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The management of acute postoperative pain has been 
dominated by an outdated conceptualization of pain. I 
Pain is viewed as the endproduct of a passive transmis-
sion system that faithfully transmits a peripheral signal 
to the spinal cord and on up to a pain center in the brain. 
This view has led to an approach to managing postopera-
tive pain that does not provide adequate control of pain, 
in part because it focuses on treating the patient only after 
the pain is well entrenched. Patients are transported to 
the recovery room after surgery, often in agonizing pain, 
where they then receive incremental doses of opioids in 
an effort to reduce already established pain. However, 
basic science and clinical data show that brief, noxious 
inputs or frank injury due to C-fiber activation (e.g. cut-
ting tissue, nerve, and bone) induce long-lasting changes 
in central neural function that persist after the offending 
stimulus has been removed or the injury has healed.2 The 
recognition that the processes involved in pain percep-
tion involve a dynamic interplay between peripheral and 
central mechanisms is inconsistent with the Simplistic 
notion that pain results from transmission of impulses 
aiong a straight through pathway from the site of injury 
to the brain. 
The practice of treating pain only after it has been 
established is slowly being supplanted by a preventive 
approach that aims to block transmission of noxious 
inputs before, during, and after surgery. The idea behind 
this approach is not simply that it reduces nociception 
and stress during surgery - although these are obviously 
worthwhile goals. The hypothesis is that the transmission 
of noxious afferent input from the periphery (e.g. arising 
from preoperative pain, incision, noxious intraoperative 
events, and postoperative inflammation and ectopia) to 
the spinal cord induces a prolonged state of central neu-
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ral sensitization or hyperexcitability that amplifies sub-
sequent input from the wound and leads to heightened 
postoperative pain. By interrupting the transmission of 
noxious perioperative inputs to the spinal cord at various 
points in time throughout the perioperative period, a pre-
ventive approach can significantly reduce the induction 
of central sensitization, resulting in reduced pain inten-
sity and lower analgesic requirements. 
The goal of this chapter is to critically review the lit-
erature that examines the effect of the timing of adminis-
tration of a variety of analgesic and anesthetic agents on 
postoperative pain and analgesic consumption. The first 
section provides a brief review of the history and recent 
progress in preemptive analgesia, followed by a descrip-
tion of the targets of a preemptive analgesic approach, 
and the definitions of preemptive and preventive anal-
gesia used in the present review. Experimental designs 
are outlined that distinguish preemptive and preven-
tive analgesia. The second section describes the criteria 
used for including studies in the present review and the 
experimental designs and treatment combinations that 
have been used in clinical studies that alter the timing 
of administration of analgesic agents. In the third sec-
tion, the outcomes of the identified studies are reviewed 
according to the target agent(s) administered, the timing 
of administration relative to incision, route and dose of 
administration, and use of additional analgeSiC agents 
in the perioperative period. Outcomes are described in 
terms of the presence or absence or a preemptive or pre-
ventive effect. The final section concludes with recom-
mendations for future research. Throughout the chapter, 
an attempt is made to highlight the enormous variability 
present in many aspects of the clinical studies. 
DEFINITIONS AND TERMINOLOGY 
History and recent progress in preemptive 
analgesia 
The possibility that pain after surgery might be amplified 
by the noxious events induced by surgical incision was 
initially put forward by Crile3 and more recently by Wall, 4 
who coined the term "preemptive preoperative analge-
sia." Wall suggested that administration of opioids and/or 
local anesthetics before surgery might reduce the central 
(spinal) neural effects of the C-fiber-induced injury bar-
rage associated with incision and thereby reduce postop-
erative pain intensity. 
Since then it has been documented that, although gen-
eral anesthesia may attenuate the transmission of nox-
ious afferent information from the periphery to the spinal 
cord and brain, it does not block it. 5.6 Moreover, it appears 
that systemic opioids may not provide a sufficiently dense 
blockade of spinal nociceptive neurons to prevent central 
sensitization.) The clinical Significance of these findings 
for patients that receive general anesthesia during surgery 
is that, while they are unconscious, the processes leading 
to sensitization of dorsal horn neurons are unaffected by 
the general anesthesia or routine doses of opioids. This 
sets the stage for increased postsurgical pain and an 
increased requirement for analgesics. 
Notably absent from this first definition of preemp-
tive analgesia was the imperative to compare a preop-
erative intervention with a postoperative intervention8 
This requirement, adopted shortly thereafter, imposed a 
constraint that limited the demonstration of preemptive 
analgesia to a narrow set of experimental designs with lit-
tle potential for clinically significant effects. The almost 
exclusive focus on this narrow definition of preemptive 
analgesia had the unintended effect of diverting attention 
away from certain clinically Significant findings (e.g. from 
studies that compared a preoperative intervention with a 
placebo-controlled condition) because they did not con-
form to what had become the accepted definition of pre-
emptive analgesia. 
Since its introduction into the pain and anesthesia lit-
eratures' the concept of preemptive analgesia has evolved, 
based in part on confirmatory and contradictory evi-
dence from clinical studies, new developments in basic 
science, and critical thought. This evolution has led to 
progress in our understanding of the mechanisms that 
contribute to acute postoperative pain. The suggestion 
that surgical incision triggered central sensitization has 
been expanded to include the sensitizing effects of pre-
operative noxious inputs and pain, other noxious intra-
operative stimuli, as well as postoperative inflammatory 
mediators and ectopic neural activity. 
Targets of preemptive and preventive 
analgesia 
From a conceptual point of view, the perioperative period 
can be divided into three fairly distinct phases: preopera-
tive, intraoperative, and postoperative (Fig. 7.1). The roles 
of specific factors within these three phases (as well as the 
interaction between factors) contribute to the develop-
ment of acute postoperative pain. These factors include: 
(1) preoperative noxious inputs and pain, (2) noxious 
intraoperative inputs ariSing from the cutting of skin, 
muscle, nerve and bone, wound retraction, etc., and (3) 
postoperative noxious inputs, including those arising 
from the inflammatory response and ectopiC neural activ-
ity in the case of postsurgical nerve injury. Each of these 
factors can contribute to both peripheral and central sen-
sitization and each is a legitimate target for a preventive 
approach. The relative contribution of these three factors 
to acute postoperative pain is dependent on the surgi-
cal procedure, extent and nature of tissue damage, dura-
tion of surgery, timing of treatments relative to incision, 
pharmacological activity of the agent(s) used preopera-
tively, presence or absence of additional analgeSia intra-
operatively, nature of postoperative analgesia, and a host 
of other variables. Minimizing the negative impact of as 
many of these factors in the three phases will increase the 
likelihood of preventing the induction and maintenance 
of peripheral and central sensitization. Preventing sensi-
tization will reduce pain and analgesic requirements. 
Figure 7.1 depicts the eight possible treatment com-
binations of administering or not administering analge-
sics across the three peri operative phases (preoperative, 
intraoperative, and postoperative). The preoperative 
period encompasses interventions that begin days before 
surgery up to those administered just minutes before skin 
incision. The intraoperative period includes interven-
tions started immediately after incision up to those ini-
tiated just prior to the end of surgery (i.e. skin closure). 
The postoperative period includes interventions started 
immediately after the end of surgery and may extend for 
days thereafter. Variability in the timing of administration 
of analgesic agents is greatest in the pre- and postopera-
tive periods (e.g. from days to minutes), but even within 
the intraoperative period there is considerable potential 
for differences among studies as to when a postincisional 
intervention is administered (e.g. from minutes to hours). 
The eight treatment combinations give rise to 28 different 
two-group deSigns. 
Defining preemptive and preventive 
analgesia 
There has been substantial debate over the appropriate 
definition of preemptive analgesia.8- 18 This has led to a 
variety of different terms and considerable confusion 
over what constitutes a preemptive analgesic effect. 
Perioperative period 
Treatment 
combination Preoperative Intraoperative: Postoperative 
Figure 7 _1 Schematic representation 
showing the presence (+) or absence 
(-) of analgesic or local anesthetic 
administration during the three 
perioperative phases of surgery 
(preoperative, intraoperative, and 
postoperative). The administration or 
nonadministration of analgesics during 
the three perioperative phases yields 
eight different treatment combinations. 
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3 ------. 
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For historical purposes, and to avoid further confu-
sion, I will use the term preemptive analgesia to refer to 
evidence (Le. reduced pain and/or analgesic consump-
tion) that preoperative treatment is more effective than 
the identical treatment administered after incision or sur-
gery (e.g. treatment combinations 2;3 or 2;4 in Fig. 7.1). 
According to this definition, the only difference between 
the groups is the timing of administration of the phar-
macological agent relative to incisionB.14 As it turns out, 
the requirement that the groups be treated identically 
with the exception of timing is rarely achieved because 
it necessitates treating the two groups differently with 
respect to other potentially important anesthetic factors 
that may unwittingly influence the outcome of the study. 
Given identical analgesia, it may not be desirable or even 
safe to ensure that the groups are treated similarly with 
respect to other anesthetic agents. 
As previously noted, this definition of preemptive 
analgesia is too restrictive and narrow. 13.14.19 Demonstrat-
ing that presurgical treatment with analgesics, but not a 
placebo, lessens pain and decreases postoperative analge-
sic requirements at a time when the agents are no longer 
clinically active7.2° suggests that some aspect of postoper-
ative pain can be prevented [although the mechanism(s) 
for this effect and the time frame within which the effect 
occurs remain obscure]. Thus, I will use the term pre-
ventive analgesia to refer to results from designs that do 
not incorporate a postincision or postsurgical interven-
tion (e.g. treatment combination 1;2 or 1;8 in Fig. 7.1), or, 
if they do, the pre- and post-treatments are not admin-
istered in an identical manner (e.g. differences in dose 
or route). A preventive analgeSiC effect is demonstrated 
when postoperative pain and/or analgesic consumption 
is reduced relative to another treatment, a placebo treat-
ment' or no treatment as long as the effect is observed 
at a point in time that exceeds the expected duration of 
action of the target agent. Thus, in the absence of a post-
treatment condition, the finding that pain or analgesic 
consumption is reduced relative to an untreated or pla-
cebo-controlled condition is evidence of a preventive 
analgesic effect; such a design, however, does not provide 
information about the factors underlying the effect or the 
time frame within which the effect occurred. 
Demonstration of a preventive effect does not require 
that an intervention be initiated before surgery; the tim-
ing of treatment may be during the procedure (e.g. treat-
ment combination 1;3 in Fig. 7.1) or even after surgery 
(e.g. treatment combination 1;4 in Fig. 7.1). For example, 
a preventive effect would be demonstrated if postopera-
tive administration of a local anesthetic but not a placebo 
(in the context of an unchecked injury barrage from inci-
sion and other intraoperative events) resulted in reduced 
postoperative pain and analgesic consumption after the 
effects of the local anesthetic wore ofFlZi.B4Thus. the aim 
of preemptive and preventive analgesia is to prevent or 
minimize central sensitization brought about by noxious 
preoperative, intraoperative, and postoperative stimuli. 
SEARCH STRATEGIES AND CRITERIA FOR 
INCLUDING STUDIES 
A PubMed® database search was conducted from 
December 1987 to January 2001 using the following key-
words and limiting the search strategy to English lan-
guage publications using human subjects: pre-emptive or 
preemptive anaigesia, preempts, pre-operative, preopera-
tive, post-operative, postoperative, pre-incision, preinci-
sion, post-incision, postincision, timing. The reference 
sections of the relevant articles were reviewed and addi-
tional articles were obtained if they evaluated the ques-
tion of timing of analgesic administration. 
The following criteria were used to select empirical 
studies for review in the present 
1 Randomized. 
2 Double-blind assessments of pain and analgesic use. 
3 Report of pain using a reliable and valid measure. 
4 Report of analgesic consumption. 
5 For studies that assess the effect of timing accord-
ing to the preventive definition outlined above, mea-
sures of pain and analgesic consumption reported at 
a point in time that exceeds the duration of action of 
the target agent whose effect on postoperative pain 
is being examined. This criterion was included to 
ensure that the observed effects are not simply anal-
gesic effects. 
6 The fmal criterion was the absence of design flaws, 
methodological problems, or confounds that render 
interpretation of the results ambiguous. 
Table 7.1 contains the studies that were excluded from 
review and shows which one or more of the six inclusion 
criteria were not met. 
The results of the PubMed® search and subsequent 
review of identified articles resulted in 148 clinical stud-
ies that met the above inclusion criteria. Table 7.2 shows 
the various experimental designs and the frequency with 
which they were used across the 148 studies and specifi-
cally for the different classes of analgesic and anesthetic 
agents. For each design, the table also shows whether 
the effect being evaluated is preemptive or preventive 
as defined above. The enormous variability in timing of 
treatment is evident from the fact that 29 different designs 
have been implemented. Table 7.3 summarizes the out-
comes of the studies reviewed below according to the 
target agent administered. Positive studies are those that 
report a significant preemptive or preventive effect (I.e. 
reduced pain or analgesic consumption or both). Nega-
tive studies are those for which the timing of treatment 
had an effect that was not significantly different from the 
control condition. Also listed is the frequency of studies 
reporting effects opposite to that predicted. 
UTERAlURE REV I EW 
Timing of administration of local 
anesthetics 
Table A7.1 describes the 59 studies that were found to 
have examined the timing of administration of local 
anesthetic agents relative to incision. A variety of surgi-
cal procedures has been studied, including third molar 
extraction,14**:15.1S**.77 tonsillectomy,1B**-80.S1.82**.83 thy-
roid surgery,84**.8S** cholecystectomy,86.88 laparoscopic 
surgery,89**-91.92,93**,94** inguinal hernia repair,11**.22**, 
95,90**.97**.98.99**·101.102**,103 appendectomy, !G7-I09 circumci-
sion,104 hypospadias repair, 106** major abdornihal~gyne­
cological surgery, 110-113.114**.115** cesarean section, 116**-119 
lower abdominal surgery, 120** laparotomy, 121 lumbar dis-
kectomy,122** arthroscopic knee surgery,123 posterolat-
eral thoracotomy,124** hemorrhoidectomy,125.116 breast 
biopsy,127 strabismus surgery,liB and hand and forearm 
surgery. 129 
The most frequent designs compared preoperative 
administration of a local anesthetic with a placebo or 
another active agent (I.e. evaluation of preventive effects). 
The next most commonly used designs compared preop-
erative administration of a local anesthetic with the same 
agent administered intraoperatively, postoperatively, or 
both preoperatively and postoperatively (Tables 7.2 and 
7.3). Local anesthetics were administered by cutaneous, 
subcutaneous, and fascial infiltration, wound infiltration, 
topical spray, nerve blocks, and by the epidural and spi-
nal routes. 
Across these various factors, there is a significant 
difference in outcome between studies that evaluate 
preemptive compared with preventive effects of local 
anesthetics (Table 7.3). Specifically, there is a greater 
proportion of positive preventive effects than 
would be expected by chance alone. Seventy percent 
(16/23) of the preemptive effects evaluated using local 
anesthetics do not show a superiority of pre- versus 
postincisionailsurgical administration, whereas 30% do. 
On the other hand, 65% of the comparisons examining 
preventive analgesia show significant preventive effects 
(beyond the duration of action of agents used). Taken 
together, these data support the idea that, for the majority 
of studies, blocking noxious intraoperative factors inter-
feres to the same degree with the development of central 
sensitization as does blocking posteroperative factors 
(I.e. these factors contribute equally to central sensitiza-
tion) , indicating that there is a benefit to the postopera-
tive blockade. What we do not know is the extent to which 
these factors contribute independently (I.e. additively) to 
~-.~. 
Table 7.1 Studies excluded from review in the present 
chapter for failing to meet one or more criteria" 
Reference Year Criterion not met 
Local anesthetics 
23 1983 P 
24 1984 R. DB, P 
25 1990 P 
26 1990 p, DF 
27 1991 DF 
28 1991 R, DB 
29 1991 A 
30 1992 P 
31 1994 R,DB 
32 1995 OF 
33 1996 OF 
34 1996 A,DA 
35 1996 P 
36 1996 DB, p, DF 
37 1998 R 
38 1998 DA 
39 1998 A 
40 1999 A 
41 2000 DB 
Nonsteroidal anti-inflammatory drugs 
42 1986 DA 
43 1987 DA 
44 1987 OF 
45 1988 DA 
46 1990 DA 
47 1991 DA 
48 1991 DA, DF 
49 1994 DF 
50 1994 DA 
51 1996 DF 
52 1996 DA, DF 
53 1997 R 
central sensitization This can only be ascertained by 
incorporating appropriate control conditions (e_g. treat-
ment combinations 1 and/or 8) into the classical tviO-
group model of preemptive analgesia. 
Tonsillectomy 
Seven studies examined the efficacy of preoperative topi-
cal anesthesia or a local anesthetic infiltration in reducing 
pain and analgesic consumption after tonsillectomy.18~ 
83.130 Three studies81 -83 evaluated both preemptive and 
preventive analgesic effects: the remaining studies eval-
uated only preventive effects. Overall, significant pre-
ventive analgesic effects were found five of the seven 
studies.?s*Ho.sz**.130** Significant preemptive analgesic 
effects were not observed, suggesting that preoperative 
and postoperative blockade are equally effective in mini-
mizing postoperative central sensitization. This conclu-
sion seems defensible given that all but two studies81.83 
showed Significant preventive effects when the preop-
erative local anesthetic infiltration was compared with 
Reference Year Criterion not met 
54 1998 DB 
55 1998 OF 
56 1998 R 
57 1999 DA 
58 2001 DB 
Opioids 
59 1991 DA 
60 1991 DA 
61 1992 DA 
62 1992 R,DB 
63 1999 DA 
64 2000 A, DA 
N-Methyl-D-aspartate antagonists 
65 1999 P 
local anesthetics and opioids 
66 1988 DB 
67 1992 R 
68 1993 P, DA 
69 1998 P,A 
Multimodal analgesia 
70 1994 R. DB 
71 1996 A 
72 1999 R, DB 
73 2000 DB 
a. R, randomized; DB, double-blind assessments; P, report of pain 
using a reliable and valid measure; A, report of analgesic con-
sumption; DA, for studies that assess the effect of timing using 
the definition of preventive analgesia outlined in the chapter, 
measures of pain, and analgesic consumption reported at a point 
in time that exceeds the duration of action of the target agent; 
OF, absence of design flaw, methodological problem, or con-
found that renders interpretation of the results ambiguous_ 
preoperative saline or a no treatment control condition. 
The two studies that falled to find preventive effects may 
be explained by use of either a topical lidocalne (ligno-
caine) spray along with two nonsteroidal anti-inflamma-
tory drugs (NSAIDs)81 or too small a dose ofbupivacaine 
(2mlO.2S%).83 
In general, the magnitude and duration of the pre-
ventive effects are impressive and clinically Significant, 
especially considering that patients received only a single 
preoperative infiltration. Pain, either at rest or at rest and 
after swallowing, was found to be significantly less intense 
than the control group for up to 8-10 days aftertonsilIec-
tomy_J8**·79**.80.**130** 
Laparoscopic surgery 
Six studies examined the effects of timing of intraperi-
toneallocal anesthetic spray or infiltration by preventive 
anaigesia,89**,90**.92.94** or both preventive and preemp-
tive analgesia,91**.93** for Japaroscopic surgery, including 
cholecystectomy, tubal ligation, and diagnostic gyneco-
Table 7.2 Variety and frequency of experimental designs used to evaluate the timing of administration of different classes of analgesic agents relative to incision 
Design Preemptive and! Treatment combination local NMDA LAs and Total number 
number or preventive (Fig. 7.1) anesthetics Opioids NSAIDs antagonists opioids Multimodal of studies 
PV 1;2 14 3 4 10 1 2 34 
2 PE and PV 1;2;3 6 2 4 13 
3 PE and PV 1;2;3;5 1 
4 PE and PV 1;2;3;6 1 
5 PE and PV 1;2;4 3 4 
6 PE and PV 1;2;7;8 1 
7 PV 1;3 7 8 
8 PV 1;3;5 1 1 
9 PV 1;4 3 3 
10 PV 1;5 2 4 2 8 
11 PV 1;8 1 1 
12 PV 2 1 2 1 4 
13 PE 2;3 7 10 4 2 24 
14 PE 2;4 7 2 1 10 
15 PE and PV 2;4;6 1 1 2 
16 PE or PV 2;5 1 4 
17 PE 2;6 4 5 
18 PE 2;7 1 
19 PV 3;5 2 
20 PV 4 
21 PV 4;5 
22 PV 4;6 2 
23 PE and PV 4;6;7 1 1 
24 PE or PV 4;8 2 6 9 
25 PV 5 1 
26 PV 5;8 1 
27 PE and PV 6;8 1 
28 PE or PV 7;8 2 3 
29 PV 8 1 1 
Total 59 21 20 24 19 5 148 
Each design (column 1) is defined in terms of specific treatment combinations (column 3) depicted in Fig. 7.1. Each design is also described as evaluating preemptive and/or preventive effects. 
PE, preemptive; PV, preventive; NSAIDs, nonsteroidal anti-inflammatory drugs; NMDA, N·methyl-o·aspartate; LAs, local anesthetics. 
Table 7.3 Summary of studies according to target agent administered 
Number Preemptive effects Preventive effects Opposite Total no. 
Agent(s) ofstudi~ Positive Negative Positive Negative effects effects 
loca I anesthetics· 59 7 (10.1) 16 (23.2) 26 (37.7) 14 (20.3) 6 (8.7) 69 (100) 
Opioids 21 4 (16.7) 5 (20.8) 9 (37.5) 3 (12.5) 3 (12.5) 24 (100) 
NSAlDs 20 1 (4.2) 10 (41.7) 3 (12.5) 8 (33.3) 2 (8.3) 24 (100) 
NMDA antagonists 24 4 (12.9) 6 (19.4) 15 (48.4) 5 (16.1) 1 (3.2) 31 (100) 
LAs and opioids 19 3 (14.3) 4 (19.0) 7 (33.3) 6 (28.6) 1 (4.8) 21 (100) 
Multimodal 5 1 (14.3) 0(0) 2 (28.6) 3 (42.9) 1 (14.3) 7 (100) 
Total b 148 20 (11.4) 41 (23.3) 62 (35.2) 39 (22.2) 14 (7.9) 176 (100) 
Table shows the total number of studies, and number (%) with positive and negative preemptive and preventive effects. Also shown is the num· 
ber (%) of studies reporting effects opposite to those predicted and the total number of effects (positive, negative, and opposite), The total num· 
ber of effects exceeds the number of studies because some studies were designed to evaluate both preemptive and preventive effects, See text 
for definition of preemptive and preventive effects, 
NSAIDs, nonsteroidal anti·inflammatory drugs; NMDA, N·methyl·D-aspartate; LAs, local anesthetics, 
a, p= 0,01 for the number of positive preventive effects by Fisher's exact test. 
b, P= 0,0001 for the number of positive preventive effects by chi·squared test. 
logical procedures, Only one study did not coadmin-
ister opioids during surgeryB2 All but one92 of 
these studies showed a significant reduction in pain and! 
or morphine consumption that long outlasted the dura-
tion of of the preoperatively administered local 
anesthetic agent (Le, from 24 h to 48 h after surgery) B9**-
91.93**.94** Preoperative plus postoperative local anesthesia 
was significantly more efficacious in reducing postopera-
tive pain than 91** postoperative90**,91** or 
no supporting recent suggestions 
that prolonged blockade may maximize the preventive 
effects of local anesthesia, 13.19 
Inguinal hernia repair 
Twelve studies evaluated timing of local anesthetic block-
ade with lidocaine or bupivacaine for inguinal hernia 
repair using a field block,98,loo aerosol spray,11** infiltra-
tion,96**99** ilioinguinal nerve block/2M spinal/caudal 
anesthesia,9s**,lQ3105 or a combination of two or more 
techniques9s**97Iolloz** (two studiesio3,io5 also included 
patients undergoing other surgical procedures including 
circumcision and orchiopexy), 
Timing of administration varied considerably, with 
some studies preemptive analgesia in the nar-
rowest sense, others evaluating preventive 
nr<>,-,n,>r<llc,,,,, effects using various treatment combina-
tions, and still others evaluating preventive 
postoperative effects. 
Only one of' the five studies evaluating preemptive 
analgesia was significant; however, the effect was small 
and limited to lower opioid consumption in favor of the 
pretreated group 6h after surgery only.99** Of the five 
studies to evaluate preventive effects, three 
showed remarkably and prolonged reductions in 
pain and analgesic consumption in favor of the pretreated 
groups between and 1 0 days96*~,101** after sur-
gery. The effects were found in a recent study that 
provided thorough blockade before, during, and after 
surgery; pain while walking about was significantly lower 
up to day 5 after surgery, and by 10 only 10% of the 
pretreated patients reported paln compared with approx-
imately 50% of the control group,101** 
The two studies21 **,22** that examined preventive 
postoperative effects compared local anesthetic blockade 
of postoperative noxious inputs with a placebo and a no 
treatment control condition (Le. treatment combination 
1;3 in Fig. 7.1) in the context of an unchecked injury bar-
rage from incision and subsequent intraoperative events, 
Both studies found a preventive effect 24 h after surgery; 
pain at rest,21**,22** after movement,21** and in response 
to pressure applied at the wound21 ** were Significantly 
lower in the group administered the local anesthetic 
blockade after surgery than in the placebo or untreated 
groups, Also, significantly lower doses of postopera-
tive analgesics were found in the treated groups, These 
results suggest that postoperative noxious inputs from 
the wound contribute to central sensitization (increased 
pain, hyperalgesia) independent of the central sensitizing 
effects of incision and subsequent noxious intraoperative 
events, The results also support the argument that "nega-
tive" studies of preemptive (e,g. treatment com-
bination 2;3 in Fig, 7.1) may be due to the relative efficacy 
of postoperative blockade and not the inefficacy of pre-
operative blockade. They also point to the importance of 
implementing appropriate control conditions in studies 
of preemptive analgesia (e,g. treatment combination 1 
and/or 8 in Fig. 7.1) to allow for an unambiguous inter" 
pretation of the results. 13 
Taken together, these studies suggest that, for inguinal 
hernia repair, the contribution of postoperative noxious 
inputs to central sensitization (and hence postoperative 
pain and opioid consumption) is greater than that of nox-
ious inputs ariSing from incision, This is supported by the 
absence of any large preemptive effects and the presence 
of Significant preventive effects, most notable among 
these are the preventive postoperative effects, 
Cesarean section and abdominal gynecological 
surgery 
All four of the studies that evaluated the preventive effects 
of a preoperative ilioinguinal nerve block using bupiva-
caine for women undergoing cesarean section (C-sec-
tion) found significant effects between 24 and 48 h after 
surgery.116**-119 Six studies were found in which a pre-
emptive or preventive approach was evaluated in women 
undergoing major abdominal gynecological surgery.HO-
115 The timing relative to incision, routes of administra-
tion. and use of additional analgesics varied considerably. 
Only two of the six studies found evidence for a preven-
tive effectlI4**1 15** There were no preemptive effects. 
Summary 
Of the 69 effects that were tested (in the 59 trials), approx-
imately 48% were significant. A greater proportion of pre-
ventive than preemptive (10%) effects (Table 7.3) 
were found to be signifIcant, consistent with the expec-
tation that a postincisional or postsurgical intervention 
should attenuate, to some extent, the course of postop-
erative central sensitization. Local anesthetic infiltration 
before tonsillectomy or inguinal hernia repair appears 
to produce clinically significant reductions in pain and 
analgesic consumption that long outlast the duration of 
action of the local anesthetics; in the case of tonsillec-
tomy, the effects are particularly prolonged. 
Timing of administration of opioid 
analgesics 
Table A7.2 shows the 21 studies that were found to have 
examined the effects of altering the timing of administra-
tion of a variety of opioids, including alfentanil, fentanyl, 
morphine, meperidine (pethidine). sufentanil, tram ado!, 
and the morphine metabolite morphine 6-glucuronide 
(M6G). The studies are almost evenly divided between 
designs comparing preoperative administration with a 
placebo or an active agent (I.e. evaluation of preventive 
effects) and those evaluating preoperative administration 
against the same agent administered intraoperatively. 
postoperatively. or both preoperatively and postopera-
tively (Le. preemptive effects; see Tables 7.2 and 7.3). 
The effects of opioids have been studied on a variety of 
surgical procedures that differ widely in duration, extent, 
and nature of damage to tissue, bone, and nerve. These 
include abdominal hysterectomy,7**.13Z**13W6.137**-
139,141.143**.145 back surgery, ;42,144** major abdominal sur-
gery,134** neurosurgical procedures,149** orthopedic 
surgery,140.147**.148** postepisiotomy pain, 135** third 
molar extraction, ISO thoracotomy,131** and a variety of 
other surgical procedures. 146** 
Routes of administration include oral, intramuscular, 
intravenous, epidural, and intrathecal. Intravenous opi-
oids have been administered as a single bolus dose, l3l**. 
132**.136.137**.138.141-143**,145.146**.149** repeated bolus 
doses,l**.1J3 or as a bolus dose followed by a continuous 
infusion.7.149** With two exceptions,146**.I41** all studies 
using epidural opioids have administered a single bolus 
dose. 
Time of administration before skin incision is not 
specified in all studies. For the intravenous (LV.) route, 
most studies indicate administration is at induction of 
the general anesthesia or between 10 and 30 min before 
skin incision. Opioids administered by the epidural route 
have been given bet\veen 30 and 60 min before induction 
of the general anesthetic. The timing of treatment before 
surgery ranges between 30 min and 2 h presurgery for the 
intramuscular (Lm,) route and 1 h before surgery for the 
intrathecal route. 
There is considerable variability in the timing of the 
second intervention for studies evaluating preemptive 
effects. The second intervention was administered intra-
operatively as early as at the start of skin incisionl45 or 
1 min after incision. 136 Not surprisingly, neither stUdy 
demonstrated a preemptive effect. The absence of dif-
ferences between the groups in postoperative morphine 
consumption and pain at 24 h may be confirmation, in the 
clinical setting, of basic science findings that high-inten-
sity noxious stimulation of C-fiber affetents located in 
skin is conSiderably less effective in inducing prolonged 
central facilitation than stimulation of afferents located in 
deep tissue. 151 Since the opioid was administered a1 skin 
incision145 or 1 min after incisionl36 in the postincisional 
group, it is unlikely that damage had heen done to deeper 
tissues which contain the C-fiber afferents responsible for 
inducing long-lasting central neural hyperexcitability. 
The absence of significant preemptive effects raises 
the issue of the time-course of postincisional central 
sensitization and whether the neural hyperexcitability 
can be prevented by an early postincisional treatment. 
Electrophysiological studies in rats have shown that sec-
ond-phase formalin responses of dorsal horn nociceptive 
neurons are inhibited to the same degree when a J1 opi-
oid agonist is administered intrathecally before or shortly 
(I.e. 9min) after formalin injury.lsz However. pteinjury 
administration is significantly more effective at inhibit-
ing second-phase responses than late 30 min) post in-
jury administration. One implication of these findings for 
clinical studies is that administration of J1 opioid agonists 
may be equally effective before and after incision until a 
windup-like state has developed, but, once established, 
higher doses may be reqUired post surgery to proVide the 
same degree of postoperative pain relief. It is likely that 
central sensitization had not fully developed by the time 
of the second intervention,136.145 suggesting that the pre-
emptive analgesic potential of the opioid was missed by 
virtue of too early a postincisional intervention. 
The remaining studies administered the second inter-
vention between lOminl33 and 15minI31 **.I43** after 
incision, later during the procedure,141 at the time of clo-
sure 132**.146**.147** or at the end or surgery.I44**.150 Two 
studies administered three interventions. the third occur-
ring intraoperatively' 38 or 10 h after surgery.14D 
Significant effects were observed in eight 
studies. significant preemptive 
effects in three studies, IJIH.143**.I44** and both preemp-
tive and preventive effects in one study'12*'" for a total of 
13 (54%) significant effects (1able 7.3). Overall. the mag-
nitude of the significant effects ranges from smalF**· 
131**.132**.137**.143**.149** to moderate. with maximum 
mean intergroup differences in visual analog scale (VAS) 
pain scores (lOO-mm scale) at rest between lOmm and 
20 mm at 24 h 144** to 48 h 134**.131**.146**.147** after surgery. 
In two studies. 146**.141** differences in VAS pain scores of 
approximately 15 mm in favor of the pretreated group 
were accompanied by a mean difference of between 3 and 
4 mg epidural morphine. increasing the overall magni-
tude of the preventive effects. 
Two recent lines of basic research are relevant to the 
efforts to prevent central sensitization by the preoperative 
administration of opioids. First, there is a growing body 
of evidence suggesting that opioid administration may 
lead to the development of acute opioid tolerance 153,1 54 
and opioid-induced facilitation of nOCiceptive process-
ing, 155157 thereby increasing the requirements for postop-
erative analgesia and enhancing postoperative pain, The 
effects of opioid agonist-induced hyperalgesia are oper-
ating at cross-purposes to the effects, thereby 
reducing the overall magnitude of the preventive and 
preemptive effects of these 
Second. basic science158 clinical l59 studies indicate 
that coadministration of opioid and low-dose 
opioid antagonists (e.g. naloxone. naltrexone) actually 
enhance opioid analgesia. in part by reducing acute opi-
oid tolerance. ISO In two recent clinical studies, Aida et 
al. 14S**.141** administered epidural morphine or saline 
before surgery followed by Lv, naloxone (O.OOBmg/kg) 
after skin closure in order to "erase the aftereffects of the 
morphine." Both studies reported significant preventive 
effects [reduced pain and lower epidural patient -con-
trolled analgesia (peA) requirements] that extended up 
to 48 h after surgery. These data raise the pos-
Sibility that the relatively large preventive effects observed 
in these studiesI46**,141** may be due to the combined 
actions of morphine and naloxone in preventing acute 
tolerance, 
In summary, of the 24 effects tested in the 21 stud-
ies reviewed, approXimately 38% and 21% showed 
nilkant preventive and effects respectively, 
Thus, a total 59% of the effects tested showed that pain 
and/or analgeSiC consumption were reduced by altering 
the timing of administration of opioid analgesics rela-
tive to incision or after the analgesic effect of the opioid 
had worn off. The lower pain and opioid-spar-
ing effect were observed in large part between 24 and 48 h 
after administration of the opioid used to prevent 
or preempt pain, 
Two-group studies that did not find Significant differ-
ences in pain and analgeSiC consumption between pre-
and postincision groups are difficult to interpret because 
of the absence of an appropriate control group (e.g. treat-
ment combination 1 in Fig, 7.1). The negative results may 
point to the relative efficacy of postincisional or postop-
erative blockade and not the inefficacy of preoperative 
blockade. Other explanations for the negative findings 
include the possibility that preoperative administration 
of opioid analgesics contributes to establishing acute opi-
oid tolerance and opioid-induced hyperalgesia. Taken 
together. the findings that coadministration of low-dose 
NMDA antagoniSts (see section on Timing of admin-
istration of NMDA receptor antagoniSts) and low-dose 
opioid antagonists reduce or reverse the development 
of acute opioid tolerance and opioid-induced hyperalge-
sial55 raise the possibility of increasing the magnitude of 
the preventive and preemptive analgesic effects of opioids 
in the clinical setting, 
Timing of administration of NMDA receptor 
antagonists 
A variety of agents that have an antagonistic action at the 
NMDA receptor are clinically available, including aman-
tadine, dextromethorphan, ketamine. ketobemidone, 
memantine, and methadone, At the present time. preven-
tive or preemptive arlalgesic effects have been investigated 
using ketamine or dextromethorphan but not the other 
NMDA antagonists, Although ketamine hydrochloride 161 
and dextromethorphan 162 act on a variety of receptor sys-
tems, their NMDA channel-blocking properties quickly 
became the focus of intense research once this receptor-
ion channel complex was discovered to playa critical role 
in the induction and maintenance of central sensitization 
and pathological pain. 163.1M The major mechanism pro-
posed to underlie the reduced opioid consumption and 
pain in studies of preemptive analgesic effect is the pre-
vention (or reversal) of NMDA-mediated sensitization of 
spinal cord dorsal horn neurons.19.165 The NMDA channel 
blockers dextromethorphan and ketamine are of particu-
lar interest, therefore. in testing the hypothesis that their 
administration before surgery reduces pain and analge-
sic consumption compared with saline administration or 
their administration after incision. 
TableA7.3 shows the 24 studies that were found to have 
used ketamine (n = 14) or dextromethorphan 10). 
The most frequent deSigns have compared preoperative 
administration of dextromethorphan or ketamine with a 
placebo or an active agent (I.e. evaluation of preventive 
effects), The next most commonly used designs compare 
preoperative administration of dextromethorphan or 
ketamine with the same agent administered intraopera-
tively. postoperatively. or both preoperatively and postop-
eratively (Table 7.2). 
Ketamine 
The timing of ketamine administration relative to inci-
sion has been studied on a variety of surgical proce-
dures including abdominal hysterectomy,20**.112,173**.177 
abdominal surgery,169**.171 arthroscopy,178** cesarean 
section,168** cholecystectomy,166** gastrectomy, 167**.176** 
laparoscopic cholecystectomy, 175 mastectomy, 174 and total 
knee replacement. 170** There is usually no rationale given 
for the patient population studied in spite of the fact 
that important differences clearly exist among the vari-
ous surgical procedures that may have a bearing on the 
outcome of the results duration of procedure rela-
tive to that of the target agent, extent (deep vs. superficial) 
and nature (nerve, muscle, viscera) of tissue damage and 
inflammation]. 
Ketamine has been administered via the intra-
venous20**·166**.168**.16S**.I71.IH.175.177.17S** and epidu-
ral167**,170**.171.173**.I'I6** routes. Intravenous ketamine has 
been administered as a single bolus dose,166**.168**.lH.l75. 
177.l78** repeated bolus doses,172 or as a bolus dose fol-
lowed by a continuous infusionl°**.169** for the duration 
of the surgical procedure. Intravenous bolus doses of ket-
amine have ranged from 0.15 mg/kgupto 2.0mg/kg, with 
the majority between 0.4 mg/kg and 1.0 mglkg Lv. 
There is somewhat less variability in the dose of ket-
amine administered by the epidural route. The five stud-
ies of epidural ketamine administered a single bolus 
dose of 30 mg173** or 60 mg, 167**.171 repeated bolus doses 
between 10 and 20 mg, 170** or a bolus dose of 1.0 mg/kg 
followed by a continuous infusion of 0.5 mg/kg/h until 
closure. 
The surgical procedures were performed under gen-
eral anesthesia in all but one of the studies. the exception 
being a positive study of patients undergoing total knee 
replacement with a combination of epidural lidocaine, 
morphine. and ketamine. 110** 
Certain studies have combined ketamine with other 
agents, including acetaminophen (paracetamol), 175 mor-
phineI67** or morphine and lidocaine, 170 making it diffi-
cultto separate the effect ofketamine from that of the other 
agents on postoperative pain and analgesic consumption. 
In seven studies, an opioidI66**.IGS**.173**.174177,17S** or an 
opioid plus an NSAIDI75 (preceded by preoperative local 
anesthetic infiltration) were administered as premedica-
tion or at induction of the general anesthesia. 
Of the five studies that administered ketamine without 
opioids, three showed a preventive effect up to 2 days after 
surgery20**.169**.116** and two showed no effect of preop-
erative ketamine. but these latter studies did not include 
an appropriate control condition (Le. treatment combi-
nation 1 in Fig. 7.1). Thus, ketamine appears to produce a 
preventive effect when administered alone. The coadmin-
istration of ketamine with an opioid appears to produce 
greater effects than that of morphine alone or ketamine 
alone. as illustrated by Aida et aJ.,l76** who found that 
epidural morphine plus Lv. ketamine produced a preven-
tive effect at 24 hand 48 h after surgery when compared 
with epidural morphine plus Lv. saline or epidural saline 
plus Lv. ketamine. The magnitude of the effect of epidural 
morphine appeared to equal that of Lv. ketamine alone. 
The exact time of administration before skin inci-
sion is not specified in all studies, but it appears to be 
3-10 min for the Lv. route and 20-30min for the epidu-
ral route. Timing of preoperative administration is often 
specified relative to induction rather than incision. There 
is understandably more variability in the time of admin-
istration postincision for studies evaluating preemptive 
effects or for studies in which the groups are not given 
the same dose of ketamine during the first and second 
intervention. The exact time after incision is not always 
specified; instead, it is equally common to report admin-
istration relative to a fixed surgical event (e.g. removal 
of specimen, wound closure). Because of this and inter-
study differences in the duration of the various surgical 
procedures. an accurate estimate of the interval between 
the first and second intervention cannot be calculated. 
However, the timing of the second intervention occurred 
between 20 and 30min postincision,17o**.m.m** at c10-
sure,169**.17I.174,175.177,178** or at end of surgery.l16** Some 
studies administered more than two interventions. 170.175 
Significant preventive effects were observed in seven 
studies,2U**.166**.168**.16S**.173**.17S**.17B** significant pre-
emptive effects in one study,167** and both preemptive 
and preventive effects in one study.170** The significant 
effects were primarily observed as an analgesia- or opi-
oid-sparing effect with the treated groups receiving or 
self-administering Significantly lower doses of postop-
erative analgesia than the untreated or placebo-treated 
groups. In two studies, the preemptive l1u*,* or preven-
tive I70**.176** effects involved both reduced pain intensity 
and reduced opioid requirements, and in one study the 
effect was a reduction in postoperative hyperalgesia. IO*" 
The majority of the significant effects were observed 
between 24 hand 48 h after surgery. 
Dextromethorphan 
Surgical procedures include laparotomy,IB8 tonsillec-
tomy,179**.IBI !owerI80** or upper l86** abdominal surgery, 
hysterectomy,184 laparoscopic cholecystectomy,183**.187** 
mastectomy,182** and hemorrhoidectomy,185** Of the 
10 studies, one1BO** examined preemptive effects, ei 
ght I79**.181.18Z**.184**-188 examined preventive effects, 
and one study examined both preemptive and preven-
tive effects. 183** Dextromethorphan has been admin-
istered by the oral,179.181.184**.187,188 Lm .. 182**.183**.I8S**. 
186** and LV.I80** routes. Oral and i.m. preparations have 
been administered in a single dose ranging from 10 mg 
to 150mg. Intravenous dextromethorphan was admin-
istered in one study as a slow infusion of 5 mg/kg over 
a 3D-min interval starting 30min before induction of 
the general anesthetic. 180** Time of administration for 
the oral route has been at least 60 min before the start of 
surgery. Time of administration for the Lm. route uni-
formly has been 30 min before incision. Time of postin-
cisional administration of dextromethorphan was after 
removal of the specimen l83** and at skin c1osure.1 8o** 
General anesthesia was administered for all but one pro-
cedure, the exception being hemorrhoidectomy per-
formed under lidocaine infiltration. 185** Intravenous 
morphine,188 Lv. fentanyl , 180**.182**.183** Lv. morphine 
and p.r. acetaminophen,181 and Lv. fentanyl and Lv. Iido-
caine I86** were administered either as a premedication or 
during surgery as a supplement to the general anesthetic. 
Only two studies did not administer an analgesic agent as 
premedication or during surgery. 119**.185 
The outcomes of the studies examining the timing of 
administration of dextromethorphan are similar to those 
of ketamine. Significant preventive effects were observed 
in six studies,6s**119**.ls2**.185-ls7** Significant preemptive 
effects in one studylsD** and both preemptive and preven-
tive effects in one study. 183** Effects were observed at least 
24 h after administration of dextromethorphan and, with 
three exceptions,6s.18o**.182** consisted of a reduction both 
in analgesics administered and in pain at rest and/or after 
movement. One study reported significantly lower pain 
intensity and analgesic consumption for 7 days after bilat-
era tonsillectomy following a single dose of 45 mg dex-
tromethorphan. 119** 
Design considerations: importance of control 
conditions 
As noted above, negative results of two-group studies 
pose a problem in interpretation because of the absence 
of an appropriate control group (e.g. treatment combina-
tion 1 or 8 in Fig. 7.1). This problem is illustrated in two 
recent studies of epidural ketaminem .113** Using a two-
group design (treatment combination 2;3 in Fig. 7.1), 
preincisional epidural ketamine (60mg) was compared 
with postincisional epidural ketamine (60mg) without 
finding the anticipated reduction in postoperative pain 
and analgesic consumption in favor of the preincisional 
group; preincisional ketamine was no better than postin-
cisional ketamine in preempting postoperative pain. 111 
Since there is no good rationale for a postincisional treat-
ment in the clinical setting (Le. one would not adminis-
ter epidural ketamine near the end of surgery without 
also having used the epidural route preoperatively), the 
impression that negative studies such as this one give is 
that neither preincisional nor postincisional treatment is 
clinically useful. 
However, as previously argued, preincisional and 
postincisional noxious stimuli make separate contribu-
tions to central sensitization. 13 It is conceivable that in 
the study by Kucuk et a1. l1l pre- and postincisional nox-
ious stimuli contributed equally to postoperative pain 
intensity so that administration of ketamine reduced 
(the respective pre- and postincisional contributions to 
central sensitization and) postoperative pain when given 
before or after incision. This possibility raises the ques-
tion of how the pre- and postincisional groups would 
have fared had they been compared with a group that did 
not receive ketamine at all. 
This question was addressed by Abdel-Ghaffar et 
a1., 173** who used the treatment combination 1 ;2;3 in Fig. 
7.l. Cumulative postoperative morphine consumption 
24 h after surgery was reduced by approximately 40% 
among patients given epidural ketamine (30 mg) before 
or after incision when compared with a control group that 
received epidural saline before and after incision (Le. no 
ketamine). Consistent with the results of Kucuk et ai., 111 
preincisional ketamine was no better than postincisional 
ketamine in preempting postoperative pain. Importantly, 
a clinically significant opioid-sparing effect was found in 
both the preincisional and postincisional groups when 
compared with the placebo-controlled group, pointing to 
the importance of a proper control condition. 
Summary 
Taken together, the results of the studies that have exam-
ined the timing of administration of ketamine or dextro-
methorphan have proved most successful in terms of the 
total percentage of studies showing significant preven-
tive or preemptive effects. As shown in Table 7.3, approx-
imately 61 % of studies have reported that administration 
of ketamine or dextromethorphan before surgery (com-
pared with after surgery or a placebo-controlled condi-
tion) results in significantly lower pain intensity and/or 
reduced analgesic requirements after the duration of 
action of the NMDA antagonists has worn off. 
The preponderance of positive studies of preemptive 
ketamine and dextromethorphan may be due not only to 
the ability of these agents to block the neural processes 
underlying central sensitization l61 but also, in a related 
vein, to their ability to attenuate the development of acute 
opioid tolerancel53.154 and reverse opioid-induced facilita-
tion of nociceptive processing.156.151 As reviewed above, 
opioids were administered (as premedication, during 
surgery, or as part of the preemptive intervention) in all 
but six of the studies. Preoperative administration of ket-
amine or dextromethorphan may have prevented acute 
opioid tolerance, opioid-facilitated activation of NMDA 
processes, and opioid-induced hyperalgesia relative to 
the control group, leading to a reduction in postoperative 
opioid requirements and postoperative pain intensity in 
the preoperatively treated groups. 
Timing of administration of nonsteroidal 
anti-inflammatory drugs 
The analgesic effects of NSAIDs have been attributed to 
their peripheral anti-inflammatory actions in inhibiting 
the synthesis of prostaglandins through the inactiva-
tion of cyclo-oxygenase. 189 This effect is an indirect one 
in that prostaglandins themselves do not produce pain 
but sensitize receptors at the site of injury to a variety of 
neurochemicals (e.g. bradykinin, serotonin, substance P, 
calcitonin gene-related peptide). Thus, at least insofar as 
their peripheral effects are concerned, NSAIDs are more 
accurately anti hyperalgesic than analgesic in action. 
Observations that the anti-inflammatory and analgesic 
effects of NSAIDs could be dissociated raised the pos-
sibility of a central site of action for these agents. IH9 The 
spinal effects of NSAIDs are not as well documented, but 
include the possibility of a nonanti-inflammatory analge-
sic action brought about by the inhibition of cyclo-oxy-
genase in the spinal cord and a consequent reduction in 
spinal NMDA-mediated events. 189.190 
When administered prior to injury, opioid agonists 
and local anesthetics prevent central sensitization by 
attenuating nociceptive processing and blocking nerve 
conduction respectively. In contrast, NSAIDs may pre-
vent central sensitization by attenuating the inflamma-
tory response, thereby reducing peripheral sensitization 
and its effects on spinal nociceptive processing. In addi-
tion to this indirect peripheral effect, the direct cen-
tral actions of NSAIDs may also contribute to reduCing 
central sensitization by preventing spinal prostanoid 
synthesis. thus reducing pre- and postsynaptic release 
of neurotransmitter (e.g. neuropeptides and excitatory 
amino aCids) from primary afferent terminals and spi-
nal interneurons. The net effect of both actions would 
be to prevent or attenuate development of a hyperexcit-
able state in spinal cord dorsal horn neurons. In terms of 
the patient's experience of pain after surgery, this would 
translate into less intense pain and a reduced requirement 
for postoperative analgesicS. 
Table A7A shows the 20 studies that were found to 
have examined the preemptive or preventive effects of 
an NSAID alone or in combination with a local anes-
thetic. Studies of patients undergoing oral surgery such 
as third molar extractionI91.193.194**.195.196.198.204 or pulpec-
tomyt92** were among the earliest to be conducted. More 
recently. other procedures have been studied, includ-
abdominal hysterectomy.203.205.209 orthopedic sur-
gery.2DO**.201**.102.206.20UIO and laparoscopy.197 Routes of 
administration include oral. rectal. Lm., and Lv. A variety 
of NSAIDs has been used. including the propionic acids. 
acetic acids. oxicams. and acetaminophen, these differing 
in the extent oftheir anti-inflammatory activity, analgesic 
effects. antipyretic actions. and pharmacokinetics. 
Of the 20 studies conducted to date, seven evaluated 
preventive effects, nine evaluated preemptive effects, and 
four both preventive and preemptive effects (Table 7.2). 
Overall, significant effects (i.e. preemptive or preventive) 
were found in 4 out of the 20 studies (20%): there was one 
preemptive analgesic effect10I ** and three preventive eff-
ects. 192**.I94**.200** 
Not only is the proportion of positive studies small. 
but the magnitude of the effects. when present, is modest 
at best. The only study20I** to report a preemptive effect 
found that cumulative Lv. PCA morphine consump-
tion was lower in the presurgery than in the postsur-
gery group up to 6 h after surgery but not later. This effect 
amounted to a mean morphine-sparing effect of approxi-
mately 1 mldh over the first 6 h after surgerv. Preventive 
effects I92**.i9'1**.200** were observed at. or up to. 24 h after 
surgery and consisted of small differences in pain and/or 
opioid consumption in favor of the pretreated group. 
In general, the ability to demonstrate preventive or 
preemptive analgesic effects using NSAIDs (vs. opioids 
or local anesthetics) is made more difficult by the fact 
that these agents do not block nociceptive processing or 
nerve conduction. As a consequence. clinical studies are 
inevitably confounded by the coadministration of sys-
temic opioids and/or a local anesthetic infiltration to all 
patients in order to provide sufficient analgeSia or anes-
thesia during the surgical procedure. This would have the 
unintended effect of reducing pain in the control group, 
thus minimizing the intergroup differences in pain and 
analgesic consumption. 
The coadministration of these agents before, during, 
and after surgery makes it difficult to assess, in a clinical 
setting, the degree to which NSAIDs, per se, contribute to 
preventive or preemptive analgeSiC effects. Nevertheless. it 
appears that from a clinical perspective NSAID treatment 
does not produce meaningful preemptive or preventive 
analgesic effects on pain or analgesic consumption over 
and above those of the analgesic and anesthetic agents 
routinely administered during the perioperative period. 
Timing of administration of local 
anesthetics and opioid analgesics in 
combination 
Table A7.5 contains a description of the 19 studies that 
examined the effects of timing of administration of a 
local anesthetic and an opioid. As shown in Table 7.2. 
designs assessing preventive analgesia212.m.2I£~219.221-214 
are considerably more frequent than preemptive anal-
gesia.21 1.214.225.226.228 Two studies examined both preventive 
and preemptive effects. 215.22o 
Effects of timing have been evaluated on a variety 
of surgical procedures, including abdominal hysterec-
tomy,21G amputation,ZZI antireflux repair.217 arthroscopic 
knee surgery, 22Q** cesarean section. "1** colonic surgery, 111 
hernia repair. 215** lower back surgery.211** posterolateral 
thoracotomy,1I7 radical prostatectomy.216**.224 third molar 
extraction,Zl9 tonsiliectomy,2lS total knee arthroplasty,214 
and upper abdominal surgery,ZI3**.218.123.22S** 
All but two of the studies115.119 used the epidural or spi-
nal route, either alone or in combination with a second 
route (e.g. intra-articular.110** infiltration212**). 
Among the studies evaluating preemptive analgesia, 
seven administered a postoperative continuous epidural 
infusion of a local anesthetic and an opioid to both the 
preoperative and postsurgical groups. The continuous 
infusion was maintained postoperatiively for 2 days217 to 
3 days11 1.213**.114.2IS.221.211 after surgery. Not surprisingly, six 
of the seven showed no effect, and only one213** reported 
a very small difference in analgesic consumption in favor 
of the preoperative grouP. 
These studies do not permit an unbiased test of the 
preemptive analgesia hypothesis because continuous 
postoperative epidural infusion would be expected to 
attenuate the development of central sensitization in both 
groups and minimize any group differences due to the 
timing of administration. Studies that examine the tim-
of treatment must allow patients to demonstrate their 
level of pain either directly, through verbal report (e.g. 
VAS pain scores). or indirectly, through their consump-
tion of postoperative analgesics. However, if the post-
operative analgesic regimen is fixed (i.e. not titrated to 
patient need, as with a continuous epidural infusion) and 
effective (pain levels are low), it may not be possible to 
detect whether the afferent barrage produced by the sur-
gical trauma had a prolonged central effect. 
Overall, seven studies (33%) showed a significant pre-
ventive effect21z**.213**.216**.22Q**.22z**.z24** and three (14%) 
showed a significant preemptive effect220**.11S**.228,,* 
(Table 7.3). The effects vary in magnitude from minor 
reductions in postoperative analgesic consumption213** to 
clinically Significant reductions in pain and/or analgesic 
consumption lasting for 4-5 days after surgeryP4**.Z2B** 
In one notable study, the incidence of pain 9weeks after 
surgery was significantly lower among patients who had 
received preoperative epidural fentanyl or bupivacaine 
than among a saline control group. 224** 
Timing of administration of multimodal 
analgesia 
The rationale for a preoperative multimodal approach 
to postoperative pain management is to capitalize on the 
combined actions of a variety of classes of analgesic and 
anesthetic agents at different receptor sites in reducing 
peripheral and central sensitization.z2g 
Five studies evaluated the effects of timing of adminis-
tration of a combination of a local anesthetic, opioid, and 
an NSAID230.231**.13z**.13l.234** (Table A7.6). Surgical pro-
cedures include lateral thoracotomy,23o.231**.234** abdomi-
nal surgery,232** and third molar extraction. 233 Not only 
are the study designs quite varied, with only one evalu-
ating the effects of the same interventions before and 
after surgery (Le. preemptive analgesia),m** but routes 
of administration for a given class of agent also differ, as 
do the durations of action of agents within and between 
classes. 
In general, the magnitude of the significant effects are 
surprisingly small given the combined use of three agents. 
For example, in the by Rockemann et a1.,232** the 
PCA morphine-sparing of a combined preopera-
tive regimen of thoracic epidural mepivicaine and mor-
phine, Lv. metamizole, and Lrn. diclofenac did not appear 
to exceed that observed by Katz et ai.,131H who compared 
preincisional with postincisional lumbar epidural fen-
tanyl. The possible exception is the study by Doyle and 
Bowler,234** who found that preoperative but not postop-
erative administration of Lv. morphine, i.rn. diclofenac, 
and intercostal nerve blocks with bupivacaine resulted in 
Significantly reduced pain on movement of about 20mm 
on a VAS from 12 h to 48 h after posterolateral thoracot-
0my. Interestingly, this study was similar in patient popu-
lation, agents used, and route of administration {of two of 
the to the study by Kavanagh et ai.,23D but oppo-
site in effect. In that study, the placebo-treated group self-
administered Significantly less PCA morphine at 48 h 
than the group treated with preoperative intercostal bupi-
vacaine nerve blocks, Lm. morphine and perphenazine, 
and p.r. indomethacin. 
RECOMMENDATIONS FOR FUTURE RESEARCH 
Relationship between preexisting pain and 
timing of analgesic administration 
Recent evidence suggests that, in the presence of presur-
gical pain, preoperative administration of analgesics does 
not lead to the anticipated lessening of postoperative 
pain or analgesic consumption, perhaps because central 
sensitization has already been established. Postopera-
tive pain and analgesic consumption were Significantly 
reduced by pre- and intraoperative epidural morphine 
but not saline for patients who did not report presurgical 
pain. 147** However, among patients with presurgical pain. 
pre- and intraoperative epidural morphine was no more 
effective than saline. It is not clear whether the absence 
of a difference in phantom limb pain or stump pain after 
amputation between groups treated with preoperative 
and intraoperative epidural morphine and bupivacaine 
versus saline221 also relates to the presence of preamputa-
tion pain and the possibility that central sensitization had 
already been established before the preoperative treat-
ment. Future studies should report presence (and dura-
tion) or absence of presurgical pain. 
Offsetting the competing effects of 
preventive opioid analgesia and opioid-
induced tolerance/hyperalgesia 
As noted above, recent basic scientific evidence points 
to the possibility that, under certain circumstances, pre-
operative administration of opioid analgesics may con-
tribute to the establishment of acute opioid tolerance l53 
and opioid-induced hyperalgesia.117.13s The mechanisms 
underlying the reduced pain and opioid consumption 
brought about by preemptive opioid analgesia, and the 
increased pain and opioid consumption underlying acute 
opioid tolerance and opioid-induced hyperalgesia, con-
cern competing processes involVing the NMDA recep-
tor-ion channel complex. These findings have important 
implications for the conduct of clinical studies evaluating 
the preeemptive and preventive effects of opioid analge-
sics since the main outcome measures (pain and opioid 
consumption) will be directly affected by the mechanisms 
underlying these competing neural processes. The net 
effect of this competition is to attenuate (or even reverse) 
the desired preemptive and preventive effects. Coadmin-
istration of opioids and low-dose NMDA antagonists or 
low-dose opioid antagonists has been found to inter-
fere with the development of acute opioid tolerancels4.236 
and opioid-induced hyperalgesia. 155 A mechanism-based 
approach to postoperative pain management involving 
coadministration of these agents would be expected to 
facilitate the preventive and preemptive analgesic effects 
of opioids in patients undergoing major surgery. 
Recommendations to improve the quality 
of studies 
Design considerations 
The importance of including a standard treatment con-
trol group in studies that aim to evaluate the effects of the 
timing of administration of drugs relative to incision was 
illustrated by example in the section on NMDA antago-
nists, but the problem is not limited to this class of agents 
(e.g. see Molliex et al.B2). Two-group studies that do find 
significant differences in postoperative pain or analgesic 
consumption between pre- and postincision groups are 
inherently flawed because of the absence of an appropri-
ate control group (e.g. treatment combination I andlor 8 
in Fig. 7.1). The negative results may point to the relative 
efficacy of postincisional or postoperative blockade and 
not the inefficacy of preoperative blockade. 
The preponderance of positive preventive studies over 
positive preemptive studies (Table 7.3) is understandable 
when one considers that both preincisional and postin-
cisional or postsurgical noxious inputs contribute to 
postoperative central sensitization. The degree to which 
noxious inputs contribute during each of these phases is 
probably dependent on a host of factors. The continued 
use of incomplete designs that consist of preincisional 
and postincisional or postsurgical conditions (e.g. treat-
ment combination 2;3 or 2;4 in 7.1) without a true 
placebo condition (e.g. treatment combination 1 in Fig. 
7.1) or a complete blockade condition (e.g. treatment 
combination 8 in Fig. 7.1) will hinder progress in OUf 
understanding of preemptive analgesia. This is because 
negative results leave us with no idea of the significance 
of the preoperative or postoperative intervention relative 
to a group that receives no treatment or total blockade. 
Adhering to the narrow definition of preemptive anal-
gesia currently accepted by many in the field will perpet-
uate problems of interpretation and will not lead to the 
evolution and progress that is needed to move us beyond 
the current state of confusion. Inclusion of appropri-
ate control conditions is essential if we are to advance 
our knowledge about the factors that contribute to acute 
Dostooerative oain. 
Measures of pain 
The most appropriate pain measurement instruments are 
patient -rated pain scales that have demonstrated reliabil-
ity and validity (e.g. VAS, numeric rating scale, McGill 
Pain Questionnaire).237 Measurement of pain with the 
patient in a resting position is reported by almost all stud-
ies. However, the measurement of hyperalgesia is impor" 
tant. The simplest and most clinically significant test of 
mechanical hyperalgesia is to have the patient perform 
a standardized movement after surgery (e.g. sitting up 
from a lying position, inspirational spirometry) and rate 
the intenSity of the pain that ensues. More sophisticated 
measures of primary and secondary mechanical hyper-
algesia include pressure algometry applied either on or 
near the wound dressing1o.81.238 or on the side of the body 
contralateral to the incision,230 measurement of thresh-
olds to electrical stimulation,141.172 temperature,181 and 
use of von Frey filaments at a distance from the wound 
to determine the extent of secondary mechanical hyper-
algesia. 132.137.187.239 Baseline (preoperative) measures are 
important as is testing at a control site (e.g. a nonif\jured 
body part) to rule out a generalized effect due to factors 
such as anXiety, anticipatory pain, or a response bias. 
Measures of analgeSiC consumption 
The degree of pain that a patient experiences in the post-
operative setting is in part a function of postoperative 
analgesic consumption. Use of patient -controlled analge-
sia (either Lv. or epidural) as a modality for postoperative 
pain management has dominated the literature on pre-
emptive and preventive analgeSia. This is largely because 
PCA is now the gold standard for postoperative pain 
management at most institutions worldwide. Analgesic 
consumption is usually the primary outcome measure 
because patients self-administer the agent to achieve a 
relatively constant pain level. However, ftom the point of 
view of demonstrating preemptive or preventive analge-
sia, analgeSiC consumption is not the most ideal measure 
because the main hypothesis deals with pain and hyper-
algesia. Allowing pain to fluctuate by holding constant 
the level of postoperative analgesics administered would 
be a more direct test of the hypothesis,zo.96 but this is not 
always feasible or ethical given the evolving standards of 
pain management practice. 
Cumulative analgesic consumption at the end of the 
study is a common measure, but report of a single value 
may not provide information that is specific enough to 
pinpoint the nature of the effect (analgeSiC or preven-
tion of central sensitization) or exactly when it occurs. 
The latter point may not be relevant if a postincision 
control group is employed. It may be especially relevant 
in studies that evaluate the preventive effect of a preop-
erative intervention (I.e. when comparing it with a pla-
cebo) since it is likely that the largest difference in PCA 
consumption between treated and untreated groups will 
occur at the time of peak effect of the target agent used 
preventively. Report of a single value of cumulative anal-
gesic consumption at the end of the study may be mis-
leading depending on the pattern of consumption over 
time. For example, if a difference in analgesic consump-
tion occurs within the first few hours after surgery (but 
not thereafter), when the effects of the analgesics used 
preventively are still active, then this is an analgesic effect. 
Likewise, report of a single value for cumulative analge-
sic consumption at the end of the study may result in fail-
ure to detect the presence of group differences at earlier 
time points. Unless cumulative analgesic consumption 
is reported at multiple times across the study period, an 
analgesic effect may be misinterpreted as a preemptive or 
preventive effect or either effect may be missed. Another 
approach that circumvents this problem is to calculate 
analgesic consumption within intervals bounded by the 
times when pain is assessed.7.l1DI3U18 This method has the 
advantage of specifying an interval within which an opi-
aid-sparing effect has occurred. 
Time from end of surgery to first request for anal-
gesics has been used as an indication of effi-
cacy. 54.65.Bl.Bl.98126.144.150.l68.173.lBl.185.1B6.205.206.m This is a valid 
measure of the duration of analgesia providing (1) the 
timing of administration of pre- and intraoperative anal-
gesia is the same for all treatment groups and (2) pain 
scores do not differ at the time of first request for anal-
gesia. However, the time interval between end of surgery 
and first analgesic request is not meaningful when the 
main intervention that distinguishes groups is the tim-
ing of administration of a target analgesic relative 
to incision.24o Since the study groups are designed to dif-
fer with respect to the timing of administration of a tar-
get agent, nonsignificant intergroup differencel38.141 in the 
time from end of surgery to the time of first request for 
analgesics is difficult to interpret A more meaningful 
measure would be time from administration of the target 
agent to the first for analgesia. But even this mea-
sure is not recommended because it can be influenced 
by analgesic and anesthetic agents administered during 
surgery, some of which may differ between the groups 
directly as a function of the target agent used preemp-
tively or preventively. 
Finally, some studies report the number of patients 
requiring rescue analgesics22.74.84.8s.94.99. i02.106.115.167.179.183.200.220 
or the number of supplemental doses of analgesics 
administered.99115119210 These measures lack the sensi-
tivity of cumulative analgesic consumption or analge-
sics administered within specified intervals. It should be 
noted that no study included for review in this chapter 
used these latter methods as the sole measure of analge-
sic efficacy. 
SUMMARY AND CONCLUSIONS 
Overall, across the classes of agents reviewed, the pro-
portion of preventive effects is greater than 
the proportion of significant preemptive effects (Table 
7.3). Sixty-two percent of the preventive effects reported 
showed Significant benefits associated with analgesic or 
local anesthetic administration that extended beyond the 
clinical duration of action of these agents. These results 
suggest that central sensitization can be minimized by a 
preventive approach aimed at blocking noxious stimuli 
during the preoperative, intraoperative, and/or postop-
erative periods. 
The proportion of significant preemptive effects also 
appears to be than that expected by chance alone. 
Although only 20 (33%) of the 61 preemptive effects that 
were reviewed found preoperative administration of 
analgesics or local anesthetics to result in significantly 
lower pain and/or analgesic consumption than adminis-
tration of the same agent(s) after incision or surgery, this 
percentage is conSiderably greater than the conventional 
type I error rate of 5% that would be expected if pre- and 
postoperative interventions did not differ in their efficacy. 
The finding that the proportion of Significant preventive 
effects is greater than the proportion of preemptive effects 
is consistent with the suggestion that for most preemptive 
studies postincisional or postoperative administration is 
as efficacious as preincisional administration. The enor-
mous variability between studies is one factor that likely 
contributes to the equivocal results when studies of pre-
emptive analgesia are considered. 
Nevertheless, even though the majority of studies 
show that there is little additional benefit to preopera-
tive administration of analgesic agents over postoperative 
administration, there is a clear advantage to adding local 
anesthetic blockade to general anesthesia under certain 
conditions. For example, local anesthetic administration 
before tonsillectomy or inguinal hernia repair appears to 
produce clinically Significant reductions in postopera-
tive pain that long outlast the duration of local anesthetic 
blockade. 
Timing of administration of opioids, with or without 
local anesthetics, is less conclusive, possibly because of 
the competing processes associated with acute opioid tol-
erance and opioid-induced hyperalgesia. There appears 
to be little evidence that the timing of administration of 
NSAIDs produces preemptive or preventive effects. Given 
the small number of studies of multimodal analgesia and 
the relatively large variability in the routes of administra-
tion, agents, timing, and patient populations, there are 
insufficient data to generate a reliable conclusion on the 
efficacy of the timing of administration of local anesthet" 
ics, opioids, and NSAIDs. Administration of the NMDA 
antagonists ketamine or dextromethorphan before sur-
gery resulted in significantly lower pain intensity and/or 
reduced analgesic requirements in approximately 61 % of 
the effects tested. 
The distinction between preventive and preemptive 
analgesia is an important one from the clinical perspec-
tive. Demonstration of preventive analgesia allows for 
a more stringent test of the extent to which postopera-
tive central sensitization is dampened than does a find-
ing of preemptive analgesia. This is because preventive 
analgesia requires pain and/or analgesic consumption to 
be reduced at a point in time after the duration of action 
of the analgesic agent used preventively. Otherwise. the 
effects are analgesic. The results reviewed above indicate 
that preventive effects are more frequent than preemptive 
effects, and in general they are of greater magnitude. It 
is ironic then that some of the most clinically important 
findings of preventive analgesia have been eclipsed by a 
decade or more of controversy over the clinical benefits 
of preemptive analgesia. 
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Table A7.1 Studies examining the timing of local anesthetic administration relative to incision 
Group: Nature and time after 
Procedure . Treatment preincision Timing of surgery of. preventive 
Reference (number of combination drug/post- Timing of preincision postincision Systemic or preemptive analgesic 
(year) patients) (Fig. 7.1' incision drug Route and dose intervention intervention analgesics· effect 
74 (1989) Third molar 1;2 GA plus: Infiltration After induction. before NA No Preventive effect - yes 
extraction G1: BUP/NA Gl. 8 ml 0.5% BUP incision on postoperation day 1 
(n=70) G2: PRI/NA G2: 8 ml 3% PRI Pain: G1 =G2<3 
G3: 0/NA Analgesics: Gl = G2 < G3 
75 (1997) Third molar 2;3 GA plus: Nerve block Before incision After removal of No Preemptive effect no 
extraction 51: 0/BUP 2 ml 0.5% BUP per nerve ('" 1 0 min after nerve tooth 
(n=38) 52: BUP/0 block) 
76 (1997) Third molar 1;2 GA plus: Intraoral injection At least 5 min before NA NS Preventive effect - yes at 
extraction G1: BUP + EPI/NA 56 mg 0.5% BUP + induction 48 h postoperation 
(n=48) G2: SAl+ EPI/NA 1 :200,000 EPI Pain: G1 <G2 
Analgesics: Gl < G2 
77 (1998) Third molar 2;3 GA plus: Nerve block After induction After removal of TEN Lv. 20mg Preemptive effect - no 
extraction 51: 0/BUP 2 ml 0.5% BUP per nerve ('" 10 min after nerve tooth ALF Lv. 2 mg 
(n= 32) S2: BUP/0 block), before incision 
78 (1989) Tonsillectomy 1;2 G1: GA only/NA Topical spray Immediately before NA G1: FEN Lv. dose Preventive effect 
(n= 38) G2: lID+EPIINA 30-40mg LID operation NS - yes on days 5 and 8 
Infiltration of postoperation 
peritonsillar tissues Pain: G2<G1 
20-30 ml of 5 mg!ml No; ready for work! 
LID 5 fLg/ml EPI school: G2 > G1 
79 (1991) Tonsillectomy 1;2 GA plus: Infiltration of 5 min before incision NA No Preventive effect 
(n=14) G1: BUP + EPI/NA peritonsillar tissues - yes up to day 10 
G2: SALINA 3-5 ml 0.25% BUP + postoperation 
1 :200.000 EPI Pain at rest: Gl < G2 
Pain on swallowing: 
Gl <G2 
80 (1993) Tonsillectomyandlor 1;2 GA plus: Infiltration of 5 min before incision NA NS Preventive effect 
adenoidectomy G1: BUP + EPI/NA peritonsillar tissues yes up to day 10 
(n=22) G2: SAL + EPI/NA 0.25% BUP + 1 :200.000 postoperation 
EPI dose NS Pain at rest: G1 < G2 
Pain on swallowing: 
Gl <G2 
Time to swallow: G1 < G2 
81 (1995) Tonsillectomy 1;2;3 GA plus: Topical spray of tonsillar 3 min before incision After removal of KETi.m. Preemptive effect - no 
(n=75) G1: lID/0 areas tonsils 1 mg/kg Preventive effect - no 
G2: 0/l1D 4 mg/kg 10% II D aeroso I DIC p.r. 2 mg/kg 
G3: 0/0 spray 
130 (1996) Tonsillectomy 1 ;2 GA plus: Infiltration of tonsils and 7 min before surgery NA ACE p.r. Preventive effect - yes 
(n=19) G1: BUPINA peritonsillar muscles 1,500mg at days 4,6, 7, and 9 
G2: SALINA 15 ml 0.25% BUP FEN i.v. 250 [1g postoperation 
Pain: G1 < G2 
82 (1996) Tonsillectomy 1;2;4 GA plus: Infiltration of After induction, 5 min After surgery, FEN i.v. 3 ~lg/kg Preemptive effect - no 
(n=68) G1: BUP + EPI/0 peritonsillar tissues before surgery before awakened Preventive effect - yes at 
G2: SAL + EPI/0 6-9 ml 0.25% BUP + from GA 17 h postoperation 
G3: 0/BUP + EPI 1 :200,000 EPI Pain: G1 = G3 < G2 
83 (2000) T onsi lIectomy 1;2;4 GA plus: Peritonsillar infiltration 5 min before tonsillar After completion MORi.m. Preemptive effect - no 
(n=30) G1: SALl0 2 ml 0.25% BUP excision of the procedure 0.07mg/kg Preventive effect - no 
G2: BUP/0 Pain: G1 > G2 at 4 h 
G3: 0/BUP postoperation 
84 (1994) Thyroidectomy 1;4 GA plus: Infiltration of surgical NA At end of surgery FEN i.v. Preventive effect - yes at 
(n=40) G1: NA/BUP edges of wound G1: 3.72 [1g/kg 24 h postoperation 
G2: NA/0 10ml 0.5% BUP G2: 3.81 [1g/kg Pain: G1 < G2 
Analgesics: G1 < G2 
85 (1999) Thyroid surgery 1;2;3 GA plus: Infiltration of skin 5 min prior to surgery Prior to skin FEN i.v. Preemptive effect - yes 
(n=62) G1: lID/0 10m11% LID closure ",2 [1g/kg Preventive effect - yes 
G2: 0/l1D Both at 24 h 
G3: SALl0 postoperation 
Pain: G1 < G2 < G3 
Analgesics: G1 = G2 < G3 
86 (1991) Cholecystectomy 1 ;3 GA plus: G1 and G3: infiltration NA At time of closure FEN or MPE Preventive effect - no 
(n=80) G1: NA/BUP into peritoneal, fascial, dose NS 
G2: NA/BUP and subcutaneous layers 
G3: NA/SAL 40 ml 0.25% BUP 
G4: NAISAL G2andG4: 
topical into wound 
40 ml 0.25% BUP 
87 (1994) ChOlecystectomy 1 ;2 GA plus: Infiltration of cutis, 15 min before incision NA MPE i.m. 75- Preventive effect - no, 
(n=69) G1: ROP/NA subcutis, and fascia 100mg but at 74 h postoperation 
G2: ROP/NA G1: 70 ml 0.25% ROP FEN Lv. dose NS analgesics: G1 < G3 
G3: SALINA G2: 70ml 0.125% ROP (p= 0.051) 
88 (1995) Cholecystectomy 4;8 GA plus: Interpleural block Bolus 20-25 min before G2: bolus in ALF Lv. Preemptive effect - no 
(n=30) G1: BUP/BUP Bolus 20 ml 0.5% BUP incision followed by recovery room G1: 13.6 [1g/kg 
G2: SAL/BUP followed by infusion of infusion for 24 h in G1 followed by G2: 39.2 [1g/kg 
7 ml/h 0.25% BUP infusion for 24 h 
Table A7.1 Continued 
Group: Nature and time after 
Procedure Treatment preincision Ti1111 n9of surgery of preventive 
Reference (number of combination drug/post~ Timing of. preincision postineision Systemic or preemptive analgesic 
(year) patients) (Fig. 7.1) incision drug Route and dose intervention intervention analgesics' effect 
89 (1991) Laparoscopy 1;2 GA plus: Intraperitoneal After creation of NA ALF Lv. 15 lAg/kg Preventive effect yes 
G1: IO/NA infiltration pncumoperitoneum up to 48 h postoperation 
G2: SAUNA G3: 80 ml 0.5% LID + Pain: G3 G4<G1 =G2 
G3: LID + EPI!NA 1 :320.000 EPI 
G4: BUP + EPI/NA G4: BOml 0.125% 
BUP + 1 :800.000 EPI 
90 (1994) Laparoscopic 1;3;5 GA plus: Peritoneal topical spray After creation of At end of FEN i.v. 5 ~lg/kg Preventive effect - yes at 
cholecystectomy G1: SAUSAl 20ml 0.5% BUP + pneumoperitoneum, operation 24 h postoperation 
(n=421 G2: SAUBUP + EPI 1 :200,000 EPI 10 min before surgery Pain: G3 < G2 < Gl 
G3: BUP EPI! Analgesics: G3 <: G2 < G1 
BUP+ EPI 
91 (1996) laparoscopic 1;2;3;5 GA plus: Peritoneal topical spray After creation of At end of FEN Lv. Preemptive effect - yes 
cholecystectomy Gl: SAUSAl 20ml 0.5% BUP + pncumoperitoneum, operation 0.15mg/kg at 24 h postoperation 
(n= 120) G2: SAUBUP + EPI 1 :200,000 EPI 10 min before surgery Pain: G4<G2 
G3: BUP + EPI! Analgesics: G4 < G2 
BUP+EPI Preventive effect - yes at 
G4: BUP + [PI/SAL 24 h postoperation 
Pain: G3 G4<G2<:G1 
Analgesics: 
G3 = G4 < G2 < G1 
92 (1997) laparoscop ic 1;5 GA plus: Intraperitoneal After creation of At end of No Preventive effect - no 
cholecystectomy Gl: BUP/BUP infiltration pneumoperitoneum operation Pain: G1 <G2 up to Bh 
(n=80j G2: SAUSAL 15ml 0.5% BUP postoperation 
Analgesics: G1 < G2 up to 
4 h postoperation 
93 (1998) Diagnostic 1;2;3 G1: BUP/SAl Infiltration of skin and 5 min prior to incision Immediately FEN i.v. 2 ~lg/kg Preemptive effect - yes 
laparoscopy or G2: SAUBUP fascia for trocar placement before closure Preventive effect - yes 
laparoscopic tubal G3: SAUSAL 10 ml 0.5% BUP Both at 24h 
ligation postoperation: 
(n= 57) MPQ: Gl <G2 G3 
TFA: G1 >G2 G3 
94 (2000) Laparoscopic 1;2 GA plus: Infiltration into 15 min before incision NA MPE i.m. 50mg Preventive effect yes 
gynecological G1: BUP/NA cutaneous, subcutaneous, Pain: G1 <G2 at 10h 
surgery G2: SAUNA and subfascial tissues postoperation 
(n=2B) 20 ml 0.25% BUP Analgesics: G1 < G2 at 
24 h postoperation 
95 (1982) Inguinal hernia 1;2 GA plus: Infiltration of operative Immediately before NA FEN Lv. NS Preventive effect 
repair G1: LlD/NA field and IINB operation - opposite 
(n=117) G2: 0/NA SOml 0.5-1% LID Analgesics: G1 > G2 
21 (1988) Inguinal hernia 1;3 GA plus: Aerosol spray of NA Before closure NS Preventive effect yes at 
repair G1: NAiLID cutaneous and 24 h postoperation 
(n=30) G2: NAiPLA subcutaneous surface or Pain: G1 <G2=G3 
G3: NA/0 wound 200 mg LI D Pain on movement: 
G1 <G2=G3 
Pain to pressure: 
G1 <G2=G3 
Analgesia: Gl < G2 G3 
22 (1989) Inguinal hernia 1;3 GA plus: IINB NA Before dos! ng the PAP Preventive effect yes at 
repair G1: NA/BUP 10ml 0.5% BUP external oblique MPE 24 h postoperation 
(n=60) G2: NAl0 aponeurosis dose NS Pain: G1 <G2 
Analgesics: G 1 < G2 at 
12h 
96 (1990) Inguinal 1;2 G1: GA only/NA G2: Infiltration 40 ml G2: 5 min before NA No Preventive effect 
herniorrhaphy G2: GA + BUP/NA 0.25% BUP incision - yes up to day 10 
(n=36) G3: BUPINA G3: spinal 12.5 mg 0.5% G3: NS postoperation 
BUP Pain at rest: G2 G3 <G1 
Pain on movement: 
G2<G3<Gl 
Pain to pressure: 
G2<G3<Gl 
97 (1990) Inguinal 2 Spinal LID plus: Spinal LID 5% Spinal NS NA No Preventive effect - yes 
herniorrhaphy G1: BUP/NA G1: 72mg Nerve block NS up to 48 h postoperation 
(n=45) G2: 0/NA G2: 74mg Pain: G1 <G2 
IINB Analgesics: G1 < G2 
10ml 0.5% BUP 
98 (1992) Herniorrhaphy 2;4 GA plus: Inguinal field block 15 min before operation After closure but ALF Lv. 10 Ilg/kg Preemptive effect - no 
(n=32) G1: LID + EPI/0 55 mll% LID + EPI before awake and 0.5 JA.g/kgl 
G2: 0/L1D + EPI min 
99 (1992) Inguinal herniotomy 2;3 GA plus: Infiltration of surgical 5 min before incision Immediately No Preemptive effect - yes 
(n=37) Gl: LlD!0 area before skin at 6 h postoperation 
G2: 0/L1D 40m11% LID closure Analgesics: G1 < G2 
100 (1992) Inguinal 2;3 GA plus: Inguinal field block with After induction, before Before closure of FEN i. v. 1 UQ/kQ Preventive effect - no 
herniorrhaphy Gl: BUP/0 BUP incision wound layers 
(n=50) G2: 0/BUP Gl: 40 ml 0.25% 
G2: 10ml 0.5% 
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101 (1996) Inguinal 2;4 GA plus: Infiltration Before start of surgery After surgery but No Preemptive effect no 
hernioplasty G1: BUPISAL sUbcutaneously plus tlNB before end of 
(n=54) G2: SAUBUP 2.5 mg/ml. 1 mg/kg BUP anesthesia 
102 (2000)" Inguinal hernia 1;8 GA plus: Infiltration of proposed 1.5 h before skin Intraoperative! NS Preventive effect - yes 
repair Gl: BUP/BUP/BUPI incision site and field incision after wound % pain on walking: 
(n=70) BUP block of iliohypogastric closure/6 h after G 1 < G2 up to day 10 
G2: SAUSAL/SAL/SAL and ilioinguinal nerves preoperative field postoperation 
1 ml/kg BUP 0.25% block Analgesics: Gl < G2 up to 
intraoperative infiltration day 2 postoperation 
0.8 ml/kg BUP 
subcutaneous wound 
infiltration 
0.2 ml/kg BUP 
subcutaneous wound 
infiltration 
1 ml/kg BUP 
103 (1990) Hernia repair. 2;4 GA plus: Caudal block After induction before After completion NS Preemptive effect - no 
orchiopexy, Gl: BUP/0 0.5 mllkg 0.25% surgery of surgery before 
hydrocelectomy G2: 0/BUP emergence 
(n=40) 
104 (1994) Circumcision 2;4 GA plus: Caudal block 30 min before surgery Immediately after No Preemptive effect - no 
(n=25) Gl: LlD/0 0.5ml/kg 1% surgery 
G2: 0/L1D 
105 (1997) Herniorraphy, 2;4 GA plus: Caudal After induction, before After surgery, No Preemptive effect - no 
orchiopexy. G1: BUP + EPII0 0.6 ml/kg 0.25% + incision prior to 
circumcision G2: 0/BUP + EPI 1:200,000 emergence 
(n=51) 
106 (1997) Hypospadias repair 2;4;6 GA plus: Penile block Immediately before Immediately after No Preemptive effect no 
(n=98) Gl. BUP/0 Gl, G2: 0.5 mllkg 0.5% incision surgery before Preventive effect - yes 
G2: 0/BUP BUP emerging from GA up to 24 h postoperation 
G3: BUP/BUP G3: 0.25ml/kg 0.5% BUP Pain: G3 <G2 
Analgesics: G3 < G2 
107 (1994) Appendectomy 1;2;3 GA plus: Infiltration of skin and 3 min before incision At wound closure FEN Lv. Preemptive effect - no 
(n=90) G1: LID + EPII0 subcutaneous tissue G1: 118ftg Preventive effect - no 
G2: eJ/LID EPI 15 mll.S% + 1 :200.000 G2: 141 ft9 
G3: 0/0 G3: 116 ftg 
108 (1997) Appendectomy 1;5 GA plus: Infiltration of skin and Immediately before At wound closure NS Preventive effect - no 
(n=60) G1: LID + BUPI subcutaneous tissues incision 
lID+BUP 1% LID +0.5% BUP 10ml 
G2: SALlSAl 
G3: 0/0 
109 (1997) Appendectomy l;Z GA plus: Infiltration After induction, before NA FEN Preventive effect 
(n=43) Gl: LID + BUP/NA dose NS incision "minimal doses" - no but on days 3-5 
GZ: SALINA postoperation 
Analgesia: G1 < G2 
(P=0.07, two-tailed) 
110 (1992) Gynecological 1;3 GA pius: Aerosol spray of NA After closure of FEN Lv. 0.1 mg Preventive effect - no 
laparotomy G1: NA/LiD subcutaneous tissue fascia 
(n = 24) G2: NAt0 200mg LID 
111(1993) Abdominal 2;3 GA plus: Lumbar epidural 15 min before start of 15 min before MOR i.m. 7.5- Preemptive effect - no 
hysterectomy G1: BUP + EPI/0 15ml 0.5% BUP+ surgery waking at end of 10mg 
(n = 36) G2: 0/BUP + EPI 1:200,000 EPI operation 
112 (1995) Abdominal 1;2;3 GA plus: Infiltration of incision 15 min before incision At end of surgery SUF Lv. Preemptive effect - no 
hysterectomy G1: 0/0 40ml 0.5% BUP + 5 f-tg/ml before skin suture G1: 92 f-tg Preventive effect - no 
(n = 56) G2: BUP + EPI/0 EPI G2: 94 i-!g 
G3: 0/BUP + EPI G3: 96i-!g 
113 (1996) Total abdominal 2;4 GA plus: Spinal Before induction At end of MORLm. Preemptive effect 
hysterectomy G1: BUP/0 3ml 0.5% BUP operation. prior to 0.15 mg/kg - opposite at 12 h 
(n=38) G2: 0/BUP extubation postoperation 
Lv. PCA: G1 > G2 
114 (1996) Hysterectomy or 1;2 G1: BUPINA Spinal After loss of sensation NA No Preventive effect - yes 
myomectomy G2: GA only/NA 3ml 0.5% BUP to pinprick at T8, before up to 24 h postoperation 
(n=60) incision Pain at rest: G1 < GZ 
Pain on cough: G1 < G2 
Lv. PCA: G1 < G2 
115 (1996) Hysterectomy 1;2 GA+plus: Infiltration of surgical 5 min before incision NA PIR p.L 40mg Preventive effect 
(n=50) G1: BUPINA area FEN i.v. 0.3 mg - yes up to day 3 
G2: SAUNA 40 ml 0.25% BUP BPR i.m. 0.3 mg postoperation 
Analgesics: G1 < G2 
116 (1988) Cesarean section 1;3 GA plus: BiiateralllNB NA At end of surgery FEN Lv. 100i-!g Preventive effect - yes 
(n=26) Gl:NAlBUP 10ml 0.5% BUP before reversal up to 24 h postoperation 
G2: NAISAL Pain: G1 < G2 
Analgesics: Gl < G2 
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117 (1991) Cesarean section 1;3 GA plus: Infiltration of NA After closure of MOR Lv. 5- Preventive effect - yes at 
(n=Z8) Gl: NA/BUP subcutaneous tissues peritoneum 10mg 24 h postoperation 
G2: NA/SAL 0.4ml/kg 0.5% BUP i.v. PCA: Gl < G2 
118 (1994) Cesarean section 1;2;3 GA plus: Gl: bilateralllNB 10ml Before surgery NS FEN i.v. lO0i-l.g Preventive effect - yes 
(n=62) G1: BUP/0 0.5% on each side Pain: Gl < G3 up to 24 h 
G2: 0/BUP G2: wound infiltration postoperation 
G3: 0/0 20 ml 0.5% BUP Analgesics: Gl < G2 at 
20 h postoperation 
119 (1996) Cesarean section 2;5 Preoperative spi na I Spinal 15ml plus: IINB after spinal but Immediately after NS Preemptive effect - yes 
(n=46) BUP plus: IINB before incision C·seelion at 24-48 h postoperation 
Gl: BUP + EPI/0 10 ml 0.5% BUP + Pain at rest: G1 < G2 
G2: 0/BUP + EPI 1:200,000 EPI Pain on movement: 
G3: 0/0 G1 <G2 
Preventive effect 
opposite at 24-48 h 
postoperation 
Pain at rest: G2 > G3 = G1 
Pain on movement: 
G2>G3 G1 
120 (1994) Lower abdominal 2;3 GA plus: Lumbar epidural 35 min before incision 30min after No Preemptive effect yes 
surgery Gl: BUP/SAL 15 ml 0.5% BUP incision MPQ: Gl < G2 at 24h and 
(n=42) G2: SAUBUP 72 h postoperation 
Lv. PCA: Gl < G2 up to 
48h 
121 (1997) Laparotomy 2;3 GA plus: Infiltration of midline 5 min before incision Immediately FEN i.v. NS Preemptive effect 
(n=200) Gl: BUP/0 incision before skin - opposite at 24 h 
G2: 0/BUP 40ml 0.25% BUP closure postoperation 
Pain: G1 >G2 
122 (1993) Lumbar diskectomy 1;3 GA plus: Infiltration of wound and NA Immediately MOR Lv. 0.1 mgl Preventive effect - yes at 
(n=60) Gl: NAiBUP subcutaneous tissues before wound kg 24 h postoperation 
G2: NAl0 20ml 0.5% BUP closure Incidence of severe pain: 
Gl <G2 
Lv. PCA: Gl < G2 
123 (1999)' Arthroscop it knee 4;6 GA plus: Femoral three-in-one Three-in-one block Intra-articular and FEN Lv. 1.5 !-!gl Preventive effect no 
surgery Gl: ROP/ROP/ROP nerve block before surgical incision peri-incisional kg 
44) G2: SAl/ROP/SAL 40ml 0.2% ROP ROP at end of 
Intra-articular instillation surgery 
30 ml 0.2% ROP 
Peri-incisional infiltration 
20 ml 0.2% ROP 
124 (1999) Posterolateral 4;8 GA plus: Thoracic epidural Bolus 20 min before Bolus at NS Preemptive effect 
thoracotomy Gl: MEP/MEP MEP 4 mll.5% bolus incision followed by completion - yes up to 3 days and at 
(n= 70) G2: 0/MEP followed by 4 ml/h 72-h infusion of operation 6 months postoperation 
infusion followed by 72-h Pain: Gl <G2 
infusion 
125 (1990) Hemorrhoidectomy 1;4 GA plus: Perianal infiltration NA Postoperative No Preventive effect - no 
(n=40) Gl: NAIBUP + EPI 1.5 mg/kg 0.5% BUP + 
G2: NA/EPI 1 :200,000 EPI 
126 (1993) Hemorrhoidectomy 1;4 GA plus: Infiltration Before excision After excision NS Preventive effect 
(n=30) Gl: EPI/BUP 1 :200,000 EPI opposite 
G2: EPI/SAL 20ml 0.5% BUP Pain: Gl > G2 up to 
2 days postoperation 
127 (2000) Breast biopsy 2;6 GA plus: Infiltration TEN at induction, BUP After skin closure, AlF Lv. 5l-!g/kg Preemptive effect - no 
(n= 74) Gl: TEN + BUP/0 10ml 0.5% BUP 5 min before incision while still 
G2: TEN/BUP i.v. anesthetized 
20mgTEN 
128 (1998) Strabismus surgery 1;2;4 GA plus: G2: retrobulbar block 10 min before surgery At conclusion of NS Preventive effect - no 
(n=30) Gl: 0/0 2mI0.5%BUP surgery 
G2: BUP/0 G3: subcoi]unctival 
G3: 0/BUP ii]ection 0.25 ml 0.5% 
BUP 
129 (2000) Hand and forearm 2;4 GA plus: Axillary block 20 min before incision After surgery No Preemptive effect 
surgery Gl: BUP/0 2 mg/kg 0.25% BUP (15min before the - opposite at 24 h 
(no:S5) G2: 0/BUP end of GA) postoperation 
Cumulative pain: G1 > G2 
G1 >G2 
a. Administered to all patients as premedication or during surgery. 
b. This study has four interventions, the second occurring intraoperatively, the third at the end of surgery, and the fourth 6h after preoperative field block. 
c. This study has three interventions, the second and third occurring at the end of surgery. 
ACE, acetaminophen (paracetamol); ALF, alfentanil; BPR, buprenorphine; BUP. bupivacaine; Die diclofenac; i.v. peA. intravenous patient-controlled analgesia; EPI, epinephrine (adrenaline); FEN, fentanyl; GA, gen-
eral anesthesia; IINB, ilioinguinal and iliohypogastric nerve block; i.m., intramuscular; i.v., intravenous; KET. ketamine; KTO, ketorolac; LID. lidocaine (lignocaine); MEP. mepivacaine: MPE, meperidine (pethidine); 
MPQ McGill Pain Questionnaire; MOR, morphine; NA, not applicable; NS, not stated; PAP, papaveretum; PIR. piroxicam; p.r., per rectum; PRI. prilocaine; ROP, ropivacaine; Sl and 52, first and second sides of body 
in studies using patients as their own controls (i.e. within-subject design); SAL, saline; SUF. 5ufentanil; TEN, tenoxicam; 0. nothing administered. 
Table A7.2 Studies examining the effects of riming of opioid administration relative to incision 
Procedure Treatment Group: Timing of Timing of 
Reference (number of combination preincision drug! preincision postincision Systemic Nature and time after surgery of 
(year) patients) (Fig. 7.1) postincision drug Route and dose intervention intervention opioid' preventive or preemptive analgesic effect . 
131 (1992) Posterolatera I 2;3 GA plus: Lumbar epidural 30 min before 15 min after No Preemptive effect yes 
thoracotomy G1: FEN/SAL 4IA!l/kg FEN incision incision Pain: G1 < G2 at 6 h postoperation 
(n= 30) G2: SALIFEN Lv. PCA: G1 < G2 between 12h and 24h 
postoperation 
132 (1993) Abdominal 2;3 GA plus: G1: Lm. 10mg G1: 1 h Closure of No Preemptive effect - yes at 24 h 
hysterectomy G1: MOR/0 MOR preoperation peritoneum postoperation 
(n=60) G2: MORl0 G2: i.v. 10mg G2: at induction Lv. PCA: G2 < G3 
G3: 0/MOR MOR Preventive effect - yes at 24 h postoperation 
G3: Lv. 10mg Relative pain thresholds: G3 > G1 = G2 
MOR Preemptive effect opposite at 48 h 
postoperation 
Pain on movement: G2 > G3 
133 (1994) Abdominal 2;3 GA plus: Lv. One bolus at 10min after No Preventive effect - no 
hysterectomy Gl: ALF/MOR Gl: 7.5 lAg/kg ALF induction and incision 
(n= 60) G2: 0/ALF + MOR per bolus one bolus 90s 
G2: 15 lAg/kg ALF before incision 
0.2 mg/kg MOR 
134 (1994) Major abdominal 1;2 GA plus: Lumbar epidural Before induction NA FEN i.v. Preventive effect - yes up to 72 h 
G1: MORINA 5mg MOR Gl 4651lg postoperation 
G2: 0/NA G2: 9831lg Pain: Gl <G2 
i.v. PCA: Gl < G2 
135 (1994) Postepisiotomy 4 G1: MOR/SAL + SAL lumbar epidural After episiotomy Onset of episiotomy No Preventive effect - yes 
pain G2: SALIMOR + ACE 2mgMOR repair pain Pain: G1 < G2 
(n=90) 
136 (1994) Abdominal 2;3 GA plus: i.v. At induction 1 min after incision No Preventive effect opposite at 24 h 
hysterectomy G1: ALF/SAL + MOR 40 Ilg/kg ALF 10 min before postoperation 
G2: SALIALF + MOR 0.1 mg/kg MOR incision Pain at rest: Gl > G2 
137 (1995) Abdominal 2;5 GA plus: i.v. At induction Closure of No Preventive effect - yes at 48 h postoperation 
hysterectomy G1: MOR/MOR G1: 10mg/dose peritoneum Pain on movement: G2 < G1 
(n=49) G2: MOR/0 MOR 
G2: 20mg MOR 
138 (1995)b Abdominal 2;3 GA plus: i.v. 5 min before After incision of No Preemptive effect - no 
hysterectomy G1: FEN/SAUSAl G1-G3: 10 [Ig/kg induction peritoneum/after 
85) G2: SAUFEN/SAL FEN removal of uterus 
G3: SAUSAUFEN G4-G5: 1 ;.tg/kg 
G4: SUF/SAUSAL SUF 
G5: SAUSUF/SAL 
139 (1996) Abdominal 1;2 GA plus: p.o. q12hfor42h 2 h before surgery FEN Lv. Preventive effect - no 
hysterectomy G1: MOR/PLA 30mg/dose MOR before surgery 1 
(n=51) G2: PLAIMOR 
G3: PLA/PLA 
140 (1996)' Total knee 1;2;7;8 Spinal BUP plus: Spinal 1 h before Immediately after NA Preemptive effect - no 
arthroplasty G1: MORI 3ml 0.5% BUP operation the operation/10 h Preventive effect - opposite at 16 h 
(n= 41) MOR+MOR first intervention after the operation postoperation 
G2: SAlIMOR + MOR Lm. Pain: G3 > G4 
G3: MOR/SAL + SAL 0.14mg/kg MOR 
G4: SAlISAlISAL second 
intervention 
epidural 
4mg MOR 
third 
intervention 
3mg MOR 
7 (1996) Abdominal 1;5 GA plus: i.v. Bolus at NA No Preventive effect - yes up to 12 h 
hysterectomy G1: 0/NA G2: 30 [Ig/kg induction postoperation 
(n=45) G2: ALF/NA followed by 10- followed by IAA: G3 < Gl = G2 
G3: AlF/NA 20iJ,g/kg AlF hourly boluses 
G3: 100 lAg/kg in G2 and 
followed by 1- intraoperative 
2 [lg/kg/min ALF infusion in G3 
141 (1996) Abdominal 2;3 GA plus: Lv. 5 min before Ligation of round No Preemptive effect - no 
hysterectomy G1: SUF/SAL 1 [lg/kg SUF induction ligaments 
(n=39) G2: SAlISUF 
142 (1996) Back surgery 1;2 GA plus: Lv. 5min before NA No Preventive effect - no but 
G1: FEN/NA 3 [lg/kg FEN induction sensory thresholds: G1 > G2 
G2: SALINA 
150 (1997) Third molar 2;3 GA plus: Lm. 1-2h before Immediately after FEN Lv. Preemptive effect - no 
extraction G1: MPE/SAl 50mg MPE surgery surgery 1.5 
G2: SAlIMPE 
143 (1997) Abdominal 2;3 GA plus: Lv. 15 min before 15 min after No Preemptive effect yes from 48 h to 72 h 
hysterectomy Gl: AlF/0 70 [lg/kg ALF incision incision postoperation 
38) G2: 0/ALF Lv. PCA: G1 < G2 
lable A7.Z Continued 
Procedure Treatment Group: Timing of Timing of 
Reference (number of combination preincision drug/ preincision postincision Systemic Nature and time after surgery of 
(year) patients) (Fig. 7.1) postincision drug Route and dose intervention intervention opioid· preventive or preemptive analgesic effect 
144 (1997) lumbar 2;3 GA plus: lumbar epidural 60min before End of surgery MOR i.v. Preemptive effect - yes up to 24 h post 
laminectomy Gl: MOR/SAL 3mg MOR surgery 0.1 mg/kg operation 
(n=30) GZ: SAUMOR Pain: Gl <G2 
Analgesics: Gl < GZ 
TFA: Gl >G2 
145 (1998) Abdominal 2;3 GA plus: Lv. At induction, At start of skin No Preemptive effect - no 
hysterectomy Gl: MORISAL 0.3 mg/kg MOR 30 min before incision 
(n=60) GZ: SAUMOR incision 
146 (1999) limb surgery, 1;5 GA plus: Epidural Bolus 40min After skin closure NS Preventive effect - yes up to 48 h post 
radical Gl: MOR/NAl bolus of 0.06 mgl before incision operation for limb surgery and mastectomy 
mastectomy, G2: SAUSAL kg MOR followed followed by Pain: Gl <G2 
gastrectomy, by 0.02 mg/kg/h intraoperative E-PCA: Gl < G2 
hysterectomy, MOR infusion infusion until end 
appendectomy Lv. of surgery 
(n= 268) 0.008 mg/kg NAL 
147 (2000) Orthopedic 1;5 GA plus: Cervical or Bolus 40min After skin closure NS Preventive effect - yes up to 48 h post 
surgery: Removal surgery lumbar epidural before incision operation only among the group of patients 
removal (n=59); Gl: MOR/NAl bolus of 0.06 mg/ followed by without preoperative pain Ii.e. removal 
fracture (n", 56); G2: SAl/SAL kg MOR followed intraoperative surgery) 
arthritis (n = 58) Fracture surgery by 0.02 mg/kg/h infusion until end Pain at rest: Gl < G2 
G3: MOR/NAL MOR infusion of surgery Pain on movement: G1 < G2 at 12 h post 
64: SAL/SAL Lv. operation 
Arthritis surgery 0.008 maIko NAL E-PCA: G1 < G2 
65: MORINAL 
G6: SAL/SAL 
148 (2000) Open knee 1;3 GA plus: i.v. NA At beginning of ALF i.v. Preventive effect - yes up to 24 h post 
Gl: NAIMOR G1: 0.15mg/kg wound closure 20-30 fA.g1 operation 
(n",,37) G2: NA/M6G MOR kg Lv. PCA: Gl < G2, Gl < G3, G2", G3 
G3: NA/SAL G2: 0.1 mg/kg 
M66 
149 (2000) 
neurosurgical 
procedures 
(n=42) 
1;5 GA plus: 
Gl' TRAINA 
G2: TRAINA 
G3: FEN/NA 
Lv. Bolus beginning 
G1: 1 mg/kg bolus at induction 
TRA and for G2 and 
G2: 0.5 mg/kg 
bolus followed 
by 150 fJ.g/kg/h 
continuous 
infusion TRA 
G3: 2 fJ.g/kgih 
continuous 
infusion FEN 
G3 continuous 
infusion 
throughout the 
operation 
a. Opioid, other than the target intervefltion, administered to all patients as a premedication or during surgery. 
b. This study has three interventions, the third occurring after removal of the uterus. 
c. This study has three interventions, the third occurring 10 h after the operation 
NA No Preventive effect yes at 4 hand 8 h post 
operation 
Pain: G3 G2 < G1 
ALF, alfentanil; BUP, bupivacaine; E-PCA, epidural patient-controlled analgesia; FEN, fentanyl; IAA, integrated analgesic assessment; Lv., intravenous; Lm., intramuscular; M6G, morphine-6-glucuronide; MOR, 
morphine; NAL, naloxone; ACE, acetaminophen (paracetamol); MPE, meperidine (pethidine); PLA, placebo; p.o., per os; NA, not applicable; NS, not stated; SAL, saline; SUF, sufentani1; IRA, tramadol; TfA, time to 
first analgesic request; 0, nothing administered. 
Table A7.3 Studies examining the effects of timing of administration of the NMDA receptor antagonists ketamine or dextromethorphan relative to incision 
Nature and time after 
Procedure Treatment Group: Timing of Timing of surgery of preventive 
Reference (number of combination pre incision drug! preincision postincision Systemic or preemptive analge· 
(year) patients) (Fig. 7.1) postincision drug Route and dose intervention intervention analgesics· sic effect 
Ketamine 
166 (1993) Cl1olecystectomy 1;2 GA plus: i.v. Smin before NA FEN i.v. Preventive effect - yes 
(n=22) G1: KETINA 0.5 mg/kg KET incision 2 lAg/kg at 24 h post operation 
G2: SALINA AnalgesiCS: G1 < G2 
20 (1994) Transabdominal 1 ;5 GA plus: Lv. Bolus at NA No Preventive effect 
hysterectomy G1: KH/NA G1: 2 mg/kg KET bolus induction - yes up to 4811 post 
(n=27) G2: FEN/NA followed by 20 lAg/kg! followed by operation 
G3: 0/NA min infusion infusion until Hypera Iges ia: 
G2: 51lg/kg FEN bolus end of surgery G1 =G2<G3 
Followed by 
kg/min infusion 
167 (1997) Radical subtotal 2;3 GA plus: Thoracic epidural Before After removal No Preemptive effect - yes 
gastrectomy G1: MOR + KET /SAl 2mgMOR induction of specimen at 48 h post operation 
(n=60) G2: SALIMOR + KET 60mg KET Analgesics: G1 < G2 
168 (1991) Cesarean section 1 ;2 GA plus: i.v. Induction NA MOR Lv. 0.15 Preventive effect 
(n=40) G1: KETINA 1 mg/kg KET mg/kg - yes up to 2411 post 
G2: THIINA operation 
Lv. PCA: G1 < G2 
169 (1997) Abdominal surgery 3;5 GA plus: Lv. Bolus at After wound No Preventive effect 
(n=40) G1: KET/el G1: 0.5 mg!kg KET induction closure - yes up to day 2 post 
G2: 0/KET bolus followed by followed by operation 
10 ~lg/kg/min infusion infusion until i.v. PCA: G1 < G2 
G2: 0.5 mg/kg KET closure 
bolus 
170 (1997)b Total knee 7;8 G1: UD+MOR+KETI Lumbar epidural 30 min before 30min after No Preemptive effect yes 
replacement UD/UD+MOR KET First intervention incision incision/at at 72 h post operation 
(n=45) G2: LlDI 15m12% LID end of Pain: G1 <G2 
LID + MOR + KEr/ 1.5mg MOR surgery and Incident pain: G1 < G2 
UD+MOR+KET 20mg KET q12h i.v. PCA: G1 < G2 
G3: GA + SAl/MOR + KETI Second intervention Preventive effect 
UD+MOR+KET 10m12%UD - yes up to 72 h post 
1.5mg MOR operation 
20mg KET Pain: G1 <G3 
Tl1ird intervention Incident pain: G1 < G3 
10ml 0.32% LID i.v. PCA: G1 < G2 < G3 
lmgMOR 
10mg KET 
171 (1998) Upper abdominal 2;3 GA plus: Thoracic epidural 20 min before Closure of No Preemptive effect - no 
surgery G1: KETINA 60mg KET induction parietal 
(n=98) G2: NAIKET peritoneum 
172 (1998) Abdominal 5 GA plus: Lv. 3min before 25min after No Preventive effect 
hysterectomy Gl: FEN/FEN Gl: 1.5 j-tg/kg FEN and induction. incision and - no but on day 5 post 
45) G2: KET/KET 0.75 j-tg/kg q 30min 5 min before q 30min operation 
G3: MAG/MAG G2: 0.5 mg/kg KET and incision until 45min Pain: Gl = G3 < G2 
0.25 mg/kg q 30 min before end of (P = 0.054) 
G3: 20 mg/kg MAG and surgery 
q 30 min 
173 (1998) Total abdominal 1;2;3 GA plus: lumbar epidural Before 20min after ALF i.v. Preemptive effect - no 
hysterectomy G1: KET/SAL 30mg KET induction. incision Gl: 5.1 mg Preventive effect 
(n=61) G2: SAUKET incision G2: 2.5mg - yes up to 24 h post 
G3: SAUSAl G3: 4.0mg operation 
E-PCA: Gl < G2 G3 
174 (1999) Total mastectomy 2;3 GA plus: i.v. 5min before At skin SUF Lv. Preemptive effect - no 
(n= 128) G1: KETlSAl 0.15mg/kg KET incision closure Gl:19.9j-tg 
G2: SAl/KET G2: 20.4""g 
175 (1999)' Laparoscopic 6;8 Preoperative BUP Infiltration Lv. KET 3- Lv. KET KTO Lv. Preemptive effect - no 
cholecystectomy infiltration of incision BUP dose NS 10min before at skin 30mg Preventive effect - no 
(n= 60) lines plus GA plus: Lv. incision closurel ACE FEN Lv. 
Gl: (R)-KHlSAUACE 1.0mg/kg (R)-KET on arrival 1.5-2.0 j-tg/kg 
G2: SAU(R)-KETIACE p.L in recovery ALF 
G3: SAUSAUACE 1.000mgACE room 0.5-1.0mg 
176 (2000) Gastrectomy 1;5 GA plus: Thoracic epidural Epidural Immediately No Preventive effect - yes 
(n=121) G1: MOR (epidural) + SAL 0.06 mg/kg MOR bolus 40min priorto after surgery MOllement pain: 
(Lv.)/NAL (i.v.) followed by 0.02 mgl skin incision G2 < G4 at 12h post 
G2: SAL (epidural) + KET kg/h infusion followed by operation 
(Lv.) i.lI. infusion until Rest pain: 
G3: MOR First intervention skin closure G3 < G1 = G2 < G4 at 
(epidural) + KET (LII.)I 1.0mg/kg KET bolus Lv.10min 24 hand 48 h post 
NAl (i.v.) followed by 0.5 mgt prior to skin operation 
G4: SAL (epidural) + SAL kg/h infusion incision E·PCA: 
Ii. v.)/SAL (I. v.) Second intervention followed by G3 <G1 G2 <G4 at 
0.008 mg/kg NAL infusion until 24 hand 48 h post 
bolus skin closure operation 
Table A7.3 Continued 
Nature and time after 
Procedure Treatment Group: Timing of Timing of surgery of preventive 
Reference (number of combination preincision drug! pre incision postincision Systemic or preemptive analge-
jyear) patients) (Fig. 7.1) postincision drug Route and dose intervention intervention analgesics' sic effect 
177 (2000) Abdominal 1;2;3 GA plus: i.v. Smin before At end of skin ALF Lv. 15~tgl Preemptive effect - no 
hysterectomy Gl' SAL/SAL 0.4 mg/kg KET skin incision closure kg Preventive effect 
(n=99) G2: KETISAL - opposite at 60 min 
G3: SAL/KET Post operation 
pain: G3 < Gl = G2 
178 (2000) Arthroscopic 1;2;3 GA plus: Lv. 10 min after After skin SUF Lv. Preemptive effect - no 
anterior cruciate Gl: KET/SAl 0.15 mg/kg KET induction closure 0.5-0.6I-tg/kg Preventive effect - yes 
ligament repair G2: SALIKET before at 24 hand 48 h post 
(n=45) G3: SAL/SAL tourniquet operation 
inflation Lv. PCA: Gl = G2 < G3 
Dextromethorphan 
188 (1998) Laparotomy 1;2 GA plus: p.o. Night before NA MORi.v. Preventive effect - no 
(n=37) G1: DEX/NA 60mg/dose DEX and 1 h before Gl:13mg 
G2: PlAlNA surgery G2: 17mg 
179 (1998) Bilateral 1;2 GA plus: p.o. 60 min before NA No Preventive effect 
tonsillectomy Gl: DEX/NA G1: 30mg DEX arrival in OR - yes up to day 7 post 
(n=36) G2: DEl(fNA G2: 45mg DEX operation 
G3: PLA/NA Pain at rest: G2 < G3 
Pain on swallowing: 
G2<G1 =G3 
Analgesics: G1 = G2 < G3 
180 (1999) Lower abdominal 2;3 GA plus: i.v. 30 min before During skin FEN Lv. Preemptive effect 
surgery Gl: DEX/SAL 5mg/kg DEX induction over closure 3l-tg/kg - yes up to day 2 post 
(n=60) G2: SAL/DEX 30min operation 
Lv. peA: Gl < G2 
181 (1999) Adenotonsillectomy 1;2 GA plus: p.o. 60 min before NA MOR Lv. Preventive effect - no 
(n=60) G1: DEX/NA G1: 0.5 mg/kg DEX start of surgery 0.075mg/kg 
G2: DEX/NA G2: 1.0mg/kg DEX ACE p.r. 
G3: PLA/NA 25-35mg/kg 
182 (1999) Modified radical 1;2 GA plus: Lm. 30 min before NA FEN Lv. Preventive effect - yes 
mastectomy G1: DEX + CPM/NA 40mg DEX incision 2l-tg/kg at 48 h post operation 
(n=60) G2: CPM/NA 20mgCPM Analaesics: Gl < G2 
183 (1999) Laparoscopic 1;2;3 GA plus: Lm. 30 min before Removal of FEN Lv. Preemptive effect - yes 
cholecystectomy Gl: DEX + CPM/0 Gl and G2: 40 mg incision gall bladder 2IAg/kg Preventive effect - yes 
(n=90) G2: 0/DEX + CPM DEX + 20mg CPM Both at 48 h post 
G3: CPM/0 G3: 20mg CPM operation 
Pain: Gl <G2 G3 
Gl <G2=G3 
184 (2000) Total abdominal 1 ;2 GA plus: p.o. 1 h before NA FEN i.v. Preventive effect no 
hysterectomy Gl: DEXINA 150mg DEX surgery OAmg Lv. PCA: Gl < G2 from 0 
(n=50) G2: PlAiNA to 4 h post operation 
185 (2000) Hemorrhoidectomy 1;2 G1: LID + EPI + CPM/NA Infiltration Infiltration NS NA No Preventive effect - yes 
(n=60) G2: UD + EPI + DEX + 10ml 2% LID + 0.4 mg Lm. injection at 48 h post operation 
CPM/NA EPI in 30 ml SAL 30 min before Worst pain: G2 < Gl 
Lm. skin incision Analgesics: G2 < Gl 
40mg DEX 
20mgCPM 
186 (2000) Upper abdominal 1;2 GA plus: i.m. 30 min before NA FEN Lv. 21A91 Preventive effect 
surgery Gl: CPM/NA G2: lOmg intramuscular kg yes up to 3 days post 
(n=60) G2: DEX + CPM/NA G3: 20mg incision LID Lv. operation 
G3: DEX + CPMINA G4: 40mg 1.5mg/kg Cough pain: G4<Gl, 
G4: DEX + CPM/NA G2,G3 
Lv. PCA: G4 < Gl 
181 (2001) laparoscopic 1;2 GA plus: p.o. 90min before NA FEN Lv. Preventive effect - yes 
Cholecystectomy Gl: DEX/NA Gl: 90mg the operation 2.51A9/kg at 24 h post operation 
or inguinal G2: PlAiNA Pain: Gl < G2 
hernioplasty Analgesics: G1 < G2 
a. Administered to all patients as a premedication or during surgery. 
b. This study has more than three interventions, the third occurring at the end of surgery and q 12 h thereafter. 
c. This study has three interventions, the third occurring on arrival in the recovery room. 
ACE, acetaminophen (paracetamol); AlF. alfentanil; BUP, bupivacaine; CPM. chlorpheniramine maleate; DEX, dextromethorphan; E-PCA. epidural patient-controlled analgesia; EPI, epinephrine (adrenaline); FEN, 
fentanyl; GA, general anesthesia; Lm., intramuscular; Lv., intravenous; KET, ketamine; KTO. ketorolac; LID, lidocaine (lignocaine); MAG. magnesium; MOR, morphine; NA, not applicable; NS, not stated; NAl, nalox-
one; OR, operating room; PLA, placebo; p.o., per os; p.r., per rectum; SAL, saline; sur, 5ufentanif; THI, thiopentone; 0, nothing administered. 
Table A7.4 Studies examining the effects of timing of NSAlDs relative to incision 
Nature and time 
Treatment Group: Timing of Timing of after surgery of pre-
Reference Procedure (num- combination preincision drug! preincision postim:ision ventive or preemp-
(year) ber of patients) (Fig. 7.1) postincision drug Routes and doses intervention intervention Systemic opioid' tive analgesic effect 
191 (1983) Third molar 2;6 Preoperative LID + EPI Infiltration p.o. After surgery NS Preemptive effect - no 
extraction infiltration plus: 1.8ml medications (time NS) 
(n=50) 51: ACE/PLA LID + 12.5 !-tg/ml before surgery 
52: PLNACE EPI (time NS) 
p.o. 
1,000mg ACE 
192 (1987) 1;2;3;6 Preoperative LID + [PI Infiltration p.o. 3 h after first No Preemptive effect - no 
(n= 120) infiltration plus: 2% LID 1 :100,000 medications dose of FLU or Preventive effect - yes 
Gl: FLUIFLU EPI 30 min before PLA at 24 h post operation 
G2: FLUIPlA p.o. surgery, Pain: Gl G3<G4 
G3: PlAlFLU 100 mg FLU/dose 15 min before 
G4: PLAIPLA infiltration 
193 (1989) Third molar 2;6 Preoperative Infiltration p.o. 30min after No Preemptive effect - no 
extraction infiltration ± i.v. sedation agent and dose N5 medications surgery 
(n=20) plus: p.o, 30 min before 
51: DlF/PLA 1,OOOmg DIF surgery 
S2: PLA/DIF 
194 (1990) Third molar 1 ;2 GA plus: iv in 18ml Immediately NA NS Preventive effect 
extraction Gl: DICINA Gl: 1 mg/kg DIC after - yes on day 1 post 
(n= 160) G2: DICINA G3: 1 !-tg/kg FEN induction, operation 
G3: FEN/NA i.m.in3ml before surgery Pain: Gl < G3, Gl < G4 
G4: SAUNA G2: 1 mg/kg DIC Analgesics: Gl < G3, 
G4:5AL G1 <G4 
195 (1990) Third molar 2;6 Preoperative Infiltration p.o. 30 min after No Preemptive effect - no 
extraction infiltration ± i.v. sedation 2% LID + 1 :100,000 medications completion of 
(n=36) plus: EPI 30 min before surgery 
S1: NAP/PlA p.o. surgery 
S2: PLAINAP 550mg NAP 
196 (1990) Third molar 2 Preoperative infiltration Infiltration p.o. NA No Preventive effect - no 
extraction plus: 2% LID + 1 :80,000 medications 
(n~44) 51: FEB INA EPI 2h before 
52: PlAlNA p,o. surgery 
450 mg FEB 
197 (1992) Laparoscop it 1 ;2 GA plus: p.r. 2 h before NA FEN Lv. Preventive effect no 
sterilization G1: IND/NA ZOOmg IND surgery 1.5 
(n=56) GZ: PLAINA 
198 (199Z) Third molar 2 Preoperative infiltration Infiltration 20min before NA No Preventive effect - no 
extraction plus: 20mg/ml operation 
(n= 150) G1: DIC + PLA/NA LID + 12.5 [tg/ml 
G2: DIC + PLAINA EPI 
G3: PLA + PLA/NA p.o. 
Gl: 150mg DIC 
i.m. 
G2: 150 mg DIC 
199 (1993) Thoracotomy 4;6 GA plus: p.r. IND night IND after MOR Preemptive effect - no 
(n= 50) G1: IND/IND+PAP ZOOmg IND first before surgery completion of 10-20mg 
G2: 0/1ND + PAP dose and 100 mg and b.i.d. surgery and 
thereafter thereafter b.i.d. thereafter 
Lv. infusion PAP infusion 
PAP dose NS started after 
surgery for 48 h 
200 (1994) Minor orthopedic 1;2;4 GA plus: Route NS 1 h before Immediately No Preemptive effect - no 
surgery G1: NAP/PLA 1,100mg NAP surgery after surgery Preventive effect - yes 
(n= 180) G2: PLA/NAP at 24 h post operation 
G3: PLA/PLA Pain: NS 
Analgesics: 
G1 G2<G3 
201 (1995) Total hip 1;2;3 GA plus: i.v. After arrival At skin closure FEN i.v. Preemptive effect 
replacement G1: KI~/SAL 60mg KTO in OR before G1: 225 lAg yes up to 6 h post 
(n=60) GZ: SAL/KTO induction G2: 242 1A-9 operation 
G3: SAUSAL G3: Z18 lAg i.v. PCA: G1 < GZ 
Preventive effect no 
20Z (1995) Knee arthroscopy 2;5 GA plus: Lm. After At end of ALF i.v. Preventive effect - no 
(n=60) G1: PIR/BUP 20mg PIR induction, procedure, lOlAg/kg 
G2: PIR/0 infiltration of before surgery before 
incisions + intra- application of 
articular injection dressing 
20 ml 0.25% BUP 
203 (1995) Abdominal 1;2;3 GA plus: i.v. infusion Between Between skin ALF Lv. Preemptive effect - no 
hysterectomy G1: KTO/SAl 10mg KTO in 50ml induction and closure and 30!!g/kg Preventive effect - no 
(n=90) G2: SAUKTO 0.9% SAL skin incision recovery ward followed by 
G3: SAUSAL 40 IAglkg/h 
intraoperatively 
Table A1.4 Continued 
Nature and time 
Treatment Group: Timing of Timing of after surgery of pre-
Reference Procedure (nurn- combination preincision drugl preincision postincision ventive or preemp-
(year) ber of patients) (Fig. 1.1) postincision drug Routes and doses intervention intervention Systemic apioid" tive analgesic effect 
204 (1996) Third molar 2;6 Preoperative LI D + EPI Infiltration p.o. p.o. NS Preemptive eHect - no 
extraction infiltration plus: 2% + 1: 100,000 medications medications at 
(n=21) 51: DIC/PLA p.o. 1 h before the end of the 
S2: PLA/DIC 100mg DIC surgery operation 
205 Abdominal 2;7 GA plus: Thoracic epidural 30 min before 30min after No Preemptive effect 
(1996)b hysterectomy G1; BUP + DIC/0/0 20 ml 0.5% BUP incision incision/ - opposite up to 12 h 
G2: 0/BUP/DIC p.r. immediately post operation 
100mg DIC after surgery Lv. PCA: Gl > G2 
206 (1996) Minor orthopedic 2;4 GA plus: i.v. 30 min before On arrival in No Preemptive effect - no 
procedures Gl: KTO/PlA 30mg surgery PACU 
(n=60) G2: PlA/KTO 
207 (1999) Knee arthroscopy 1;2 GA plus: i.v. 1 h before GA NA AlF i.v. Preventive effect no 
(n= 100) Gl: PRO/NA 30mg/kg PRO 10p.g/kg 
G2:TEN/NA 0.5 mg/kg TEN 
G3: PRO + TEN/NA 
G4: PLAINA 
208 (2000) Laparoscopic 2;4 GA pius: i.v. In OR before At completion FEN Lv. Preemptive effect 
gynecological Gl: KTO/SAL 30mg KTO surgery of surgery 1-2p.g/kg - opposite up to 24 h 
procedures G2: SAUKTO post operation 
(n=51) Pain: G1 > G2 
209 (2000) Total abdominal 1 ;2 GA plus: Lv. 10 min before NA FEN Lv. Preventive effect no 
surgery Gl: TEN/NA G1: 20mg induction of 5 
(n=45) G2:TEN/NA G2: 40mg GA 
G3: SAUNA 
210 (2001) Knee arthroscopy 2;4;6 GA plus: p.o. 1 h 30min post No Preemptive effect - no 
(n= 121) Gl: DIC/PLA Gl: 50mg preoperation operation 
G2: PLAlDIC G2: 50mg 
G3: DIG/DIC G3: 25 
a. Administered to all patients as a premedication or during surgery. 
b. This study has three interventions, the third occurring immediately after surgery. 
AlF, alfentanil; BUr>, bupivacaine; DIC, diclofenac; DlF, diflunisal; E-PCA, epidural patient-controlled analgesia; EPI, epinephrine (adrenaline); FEB, fenbufen; FEN, fentanyl: FlU, flubiprofen; GA, general anesthe-
sia; Lm., intramuscular; IND, indomethacin: Lv., intravenous; KTO, ketorolac; LID, lidocaine (lignocaine); MOR, morphine; NA, not applicable; NAP, naproxen sodium; NS, not stated; OR, operating room; PACU, 
postanesthetic care unit; PAP. papaveretum; ACE, acetaminophen (paracetamol); PIR, piroxicam; PlA. placebo; p.o" per os; p.r" per rectum; PRO, propacetamol; SAL. saline; 51 and S2, first and second sides of 
body in studies using patients as their own controls: 0, nothing administered. 
Table A7.5 Studies examining the effects of timing of administration of a combination of a local anesthetic and opioid as the target treatments 
Nature and time 
after surgery of 
Procedure Treatment Group: Timing of Timing of preventive or pre-
Reference (number of combination pre incision drug' preincision postincision Systemic emptive analgesic 
(year) patients) (Fig. 7.1) postincision drug Route and dose intervention intervention opioid" effect 
211 (1992) Colonic surgery 4;8 GA plus: Thoracic epidural Gl: bolus 40 min G2: bolus at FEN Lv. Preemptive effect 
(n= 32) G1: BUP + MORI bolus dose before incision wound closure 0.l-O.2mg no 
BUP+MOR 7ml7.5mg/ml followed by followed by first 
G2: 0/BUP+MOR BUP+2mg MOR first infusion for infusion for 2 h 
First infusion 2 h followed by followed by second 
4ml/h 7.5mg/ml second infusion infusion for 72 h 
BUP + 0.05 ma/ml for 72 h 
MOR 
Second infusion 
4 ml/h 2.5 mg/ml 
BUP + 0.05 mg/ml 
MOR 
212 (1993) Cesarean 5;8 S1: BUP + SUF/BUP lumbar epidural Before section Infiltration of No Preventive effect 
section S2: BUP+ SUF/SAl infusion of 0.1% wound edge at -yes at 24h 
(n=28) BUP+S f.tg/ml time of closure Pain: G1 < G2 
SUF at 10-12mllh 
followed by bolus of 
0.25% BUP 
wound infiltration 
1 ml/cm 0.25% BUP 
213 (1994) Upper 8 GA plus: Thoracic epidural Epidural before Epidural infusion ALF i.v. Preventive effect 
abdominal G1: (BUP + MOR) + BUPI bolus 9 ml 0.5% induction; started 30min 1 mg - yes at 24 and 4Bh 
surgery (BUP+MOR) BUP+2mgMOR infiltration after after initial bolus Analgesics: G1 < G2 
(n~49) G2: (BUP + MOR) + 01 followed by infusion induction, before and continued 
(BUP+MOR) of 4 ml/h 0.25% surgery for 72h post 
BUP + 0.2 mg/h MOR operation 
infiltration of 
skin, SUbcutis, and 
subfascial area 
40 ml 0.25% BUP 
Table A7.5 Continued 
Nature and time 
after surgery of 
Procedure Treatment Group: Timing of Timing of preventive or pre-
Reference (number of combination preincision drug! preincision postincision Systemic emptive analgesic 
(yearl patients) CFig.7.1) postincision drug Route and dose intervention intervention opioid' effect 
214 (1994) Total knee 4;8 GA plus: Lumbar epidural Gl: bolus 30min G2: bolus at fEN i.v. Preemptive effect 
arthroplasty G1: BUP + MORI bolus dose before incision wound closure O.3mg -no 
(n;32) BUP+MOR 16m17.5mg/ml followed by first followed by first 
G2: 0/BUP + MOR BUP+2mg MOR infusion for 24 h infusion for 24 h 
First infusion followed by followed by second 
4ml/h 1.25mg/ml second infusion infusion for 24 h 
BUP + 0.05 mg/ml for 24h 
MOR 
Second infusion 
4 ml/h 0.625 mg/ml 
BUP + 0.05 mg/ml 
MOR 
215 (1994)' Tonsillectomy 4;6;7 GA plus: Infiltration of After induction, BUP after removal No Preemptive effect 
(n=35) Gl: BUP/0/FEN tonsillar tissues Smin before of tonsils in G21 -no 
G2: 0/BUP/FEN 4 ml 0.25% BUP incision FEN at end of the Preventive effect 
G3: SALl0/FEN i.v. operation - no 
1 f,lg!kg fEN 
216 (1994) Radical 4;8 G1: BUP (no GAl/FEN lumbar epidural G1: before During skin closure G2: fEN Lv. Preventive effect 
prostatectomy G2: GA + BUP/FEN BUP incision 1-2 fAg/kg -yes 
(n=96) G3: GA only/FEN Gl: bolus of 0.25 mil G2: bolus after G3: MOR i.v. Pain: Gl < G3 on day 
kg 0.5% followed by induction 0.2mg/kg 1 post operation 
0.1 ml/kg/h 0.125% ('" 20 min before E-PCA: G1 <G2=G3 
infusion incision) followed on days 2 and 3 post 
G2: bolus of 0.2 mil by infusion until operation 
kg 0.5% followed by skin closure 
0.1 ml/kg/h 0.125% 
infusion 
FEN 
217 (1996)' Posterolateral 7;8 GA plus: Thoracic epidural 30 min before 15 min after ALF i.v. Preventive effect 
thoracotomy G1: BUP + EPI/SALIFEN/ 8ml 0.5% BUP + 1: incision incision/at end of bolus + no 
(n= 45) BUP + EPI + FEN 200,000 EPI operation/infusion infusion 
G2: SALIBUP + EPI/FEN! 50f,lg FEN started in recovery G1: 12.5mg 
BUP + EPI + FEN 2 ml/h 0.125% room for 48h G2: 
G3: SAL/SAl/FEN! BUP + 1 :400,000 G3: 10.8mg 
BUP + EPI + FEN [PI + 6 ~lg!ml FEN 
218 (1996)d Upper 7;8 GA plus: Thoracic epidural BUR + MEP bolus MEP boluses No Preventive effect 
abdominal G1: BUR + MEP/MEP/01 First/third after induction, during surgeryl - no 
surgery BUR+MEP intervention 15min before BUR+MEP 
(n=40) G2: 0/MEP/BUR + MEPI bolus of 0.1 mg incision bolus after the 
BUR+MEP BUR+SmI1.5% MEP end of 
Second intervention continuous 
1.5% MEP infusion of 
intermittent boluses MEP + BUR started 
Fourth intervention after extubation 
1.7 mg/h infusion and maintained 
of 40mll.5% for 3 days 
MEP + 0.3 mg BUR 
219 (1996) Third molar 2 GA plus: Inferior alveolar 5 min before NA No Preventive effect 
extraction Sl: LID + EPI + MOR/NA nerve block and surgery no 
(n=36) 52: SAL + MOR/NA infiltration 
2m12% BUP+ 
1 :200,000 EPI 
Lv. 
0.15 mg/kg MOR 
220 (1997) Arthroscopic 2;5 Spinal with BUP plus: Spinal Spinal before 10min before No Preventive effect 
knee surgery Gl: 0/MOR 0.7-1.0mI1% BUP surgery release of thigh - yes up to 24 h post 
(n=80) G2: MOR/0 intra-articular 10min before tourniquet operation 
G3: 0/MOR Gl and G2: 2 mg intra-articular Pain: Gl = G2 =G3 = 
G4: MOR/0 MOR lavage and G4<G7 
G5: 0/BUP G3 and G4: 5 mg surgery 
G6: 0/MOR BUP MOR 
G7: 0/NaCI G5: 20ml 0.25% BUP 
G6: 2mg 
MOR + 20 ml 0.25% 
BUP 
220 (1997) Arthroscopy- 1;2;3 GA plus: Intra-articular 10 min before 10min before FEN Lv. Preemptive effect 
assisted anterior Gl: 0/MOR (20ml) intra-articular release of thigh 2 J.!g/kg - yes at 24 h post 
crudate G2: 0/MOR Gl: 2mg MOR lavage and tourniquet operation 
ligament G3: MOR/e G2 and G3: 5 mg surgery Analgesics: G2 < G3 
reconstruction G4: 0/BUP MOR Preventive effect 
(n=60) G5: e/MOR + BUP G4: 0.25% BUP - yes at 24 h post 
G6: 0/NaCI G5: 2mg operation 
MOR + 0.25% BUP Pain: G3<G6 
Analgesics: G2 < G6, 
G3<G6 
Table A1.5 Continued 
Nature and time 
after surgery of 
Procedure Treatment Group: Timing of Timing of preventive or pre· 
Reference (number of combination preincision drugl preincision postincision Systemic emptive analgesic 
(year) patients) (Fig. 1.1) postincision drug Route and dose intervention intervention opioid' effect 
221 (1997) Lower limb 4;8 GA plus: Lumbar epidural Bolus18h Second infusion FEN Lv. Preventive effect 
amputation Gl: MOR + BUPI bolus dose before operation started after 25-100 ~tg no 
(n=50) MOR BUP 2mg MOR+ 5-10ml followed by first surgery and boluses 
G2: SALIMOR + BUP 0.5% BUP infusion until end maintained for 
First infusion of anesthesia 2-3 days 
0.16-0.28 mg/h 
MOR + 4-7 ml 0.25% 
BUP 
Second infusion 
3-7mllh 0.25% 
BUP + bolus doses 
of 2-8 mg MOR 2-4 
times/day 
222 (1997) Bilateral lumbar 1 ;2 GA plus: Caudal epidural After induction, NA NS Preventive effect 
laminotomy Gl: BUR + BUPINA 0.1 mg BPR +20ml 10min before - yes up to day 5 
(n=60); G2: 0/NA 0.25% BUP incision post operation 
lumbar fusion Pain: Gl <G2 
(n= 50) in laminectomy 
patients with a 
decrease in blood 
pressure after 
caudal injection 
223 (1997) Upper 4;5 GA plus: Thoracic epidural Bolus 65min In recovery room No Preventive effect 
abdominal Gl: BUP + SUF/0 Gl: 0.2 ml/kg 0.25% before incision (316 min after opposite on days 
G2: 0/BUP + sur BUP + 1 f!g/kg SUF followed by incision) 1.4 and 5 post 
followed by 0.1 mil intraoperative operation 
kg sur 100 I-Lg in BUP boluses q 60min E-PCA: Gl > G2 
0.25% 50 ml q 60 min 
intraoperatively 
G2: 0.2 mllkg 0.25% 
BUP + 1 ua/ka SUF 
224 (1998) Radical 4;8 GA plus: Lumbar epidural Bolus prior Bolus at beginning FEN Lv. Preventive effect 
retropubic G1: 0/MOR + LID G2: FEN 20 ml 4 ~gl to induction of fascial closure G1: 39~g - yes up to day 4 
prostatectomy G2: FEN/MOR + LID kg followed by 13 ml followed by G2: 75ftg post operation 
(n= 100) G3: BUP + EPI/MOR + LID 0.75~g/kg FEN q 2h boluses q 2 h G3: 43 ftg Pain at rest: G3 < Gl 
G3: 20ml 0.5% until fascial E-PCA: G3 < G1 
BUP + 1 :200,000 EPI closure Incidence pain-
followed by 13ml free: G2 '" G3 > Gl 
BUP+EPI q 2h at 9.5weeks post 
Gl-G3: 5mg operation 
MOR+8mI2%LlD 
225 (1998) Hernia repair 2;3 GA plus: Caudal After induction. After surgery No Preemptive effect 
(n=60) G1: BUP + MOR/0 0.66 ml/kg 0.25% 15 min before yes 
G2: 0/BUP + MOR BUP + 0.02 mg/kg surgery Pain: G1 < G2 up to 
MOR 8 h post operation 
Analgesics: G1 < G2 
at 24h post 
operation 
TFA: Gl > G2 
226 (1998) Abdominal 2;3 GA pius: Lumbar epidural After induction 15 min before skin No Preemptive effect 
hysterectomy G1: SAL/BUP + FEN 15mI0.5%BUP+50 closure -no 
(n=50) G2: BUP + FEN/SAL fAg FEN 
221 (2000) Nissin antireflux 4;8 GA plus: Thoracic epidural Bolus 30-45 min After skin closure FEN Lv. at Preventive effect 
repair G1: MEP + MORI Gl: 7-13m120mgl before incision continuous induction -no 
(n= 26) BUP+MOR m12% MEP+4mg followed by infusion for 3 days 100-300 ~g 
G2: 0/BUP + MOR MOR followed by continuous FEN Lv. 
continuous infusion infusion until during 
of 6-10ml/h 2% after skin closure surgery 
MEP/continuous Gl: 325 ~g 
infusion of 4 ml/h G2: 568fAg 
2.5mgfmI0.25% 
BUP + 0.125 mg/mt 
MOR 
G2: continuous 
infusion of 4 ml/h 
2.5 mg/ml 0.25% 
BUP + 0.125 mg/ml 
MOR 
Table A7.5 Continued 
Reference 
(year) 
228 (2000) 
Procedure 
(number of 
patients) 
Upper 
abdominal or 
thoracic surgery 
(n=80) 
Treatment 
combination 
(Fig. 7.1) 
2;4 
Group: 
preincision drugl 
postincision drug 
GA plus: 
Gl: MOR/SAL 
G2: MOR + BUP/SAL 
G3: SAL/MOR 
G4: SAL/MOR + BUP 
a. Administered to all patients as a premedication or during surgery. 
b. This study has three interventions, the third occurring at the end of the operation. 
Timing of 
preincision 
Route and dose intervention 
Lumbar epidural 20 min before 
Gl/G3: 10m150j.tgl induction 
kgMOR 
G2/G4: 10ml50l-tgl 
kg MOR + 10mg 0.1% 
BUP 
c. This study has four interventions. the third occurring at the end of the operation and the fourth in the recovery room. 
d. This study has four interventions, the third occurring after the end of surgery and the fourth after extubation. 
Timing of 
postincision 
intervention 
At end of surgical 
procedure 
Systemic 
opioid' 
MORLv. 
0.1 
Nature and time 
afteuurgery of 
preventive or pre-
emptive analgesic 
effeel 
Preemptive effect 
yes up to 5 days 
postoperation 
EPI analgesia: 
GZ<G4, G2<Gl, 
Gl =G3 
ALE alfentanil; BUP, bupivacaine; BUR, buprenorphine; E-PCA. epidural patient-controlled analgesia; EPI. epinephrine (adrenaline); FEN. fentanyl; GA. general anesthesia; i.v .. intravenous; LID. lidocaine (ligno-
caine); MEP. mepivacaine; MOR. morphine; NA. not applicable; NS, not stated; S1 and 52, first and second sides in stUdies using patients as their own controls; SAL, saline; SUF. sufentanil; TFA. time to first analge· 
sic request; 0. nothing administered. 
Table A7.6 Studies examining the timing of administration of local anesthetics, opioids, and NSAlDs as the target treatments 
Treatment Group: Timing of Timing of Nature and time after sur-
Reference Procedure (nurn- combination preincision drugl preincision postincision Systemic gery of preventive or pre-
(year) ber of patients) (Fig. 7.1) postincision drug Routes and doses intervention intervention opioid· emptive analgesic effect 
230 (1994) Posterolatera I 1;2 GA plus: Lm. Lm. and p.r. NA FEN Lv. Preventive effect opposite 
thoracoto my Gl: MOR+PER+IND+BUP Gl: 0.15mg/kg medications 1 iJ-g/kg at 24 h post operation 
(n=30) + EPI/NA MOR + 0.3 mg/kg 60 min before i.v. PCA: Gl > G2 
G2: MID PLA+SAlINA PER surgery; 
G2: 0.5 mg/kg intercostal 
MID blocks after 
p.r. induction 
Gl: 100mg INO 
G2: PLA 
intercostal blocks 
G1: 15ml 0.5% 
BUP + 1 :200.000 EPI 
G2: 15ml SAL 
231 (1994) Thoracotomy 4;8 GA plus: Paravertebral 1 h before After surgery FEN i.v. Preventive effect - yes on 
(n=56) Gl: DIC + MOR + BUPI blockade surgery DIG q 12h MaR 3 J.L9/kg day 1 post operation 
DIG + MOR + BUP 10ml 0.5% BUP NS ICNB for 48 h Pain: G1 + G3 + G5 +G7 < G2 
G2: DIG MaRl p.r. +G4+G6+G8 
DIG + MOR + BUP 100mg DIG 
G3: MOR + BUPI i.m. 
DIG + MOR + BUP 10m9 MOR 
G4: MOR/DIG + MOR + BUP IGNB 
G5: DIG + BUPI 0.1 ml/kg/h 0.5% 
DIG + MOR + BUP BUP postoperatlon 
G6: DIG/DIG + MOR + BUP 
G7: BUP/DiC + MOR + BUP 
G8: 0/DIG + MOR + BUP 
Table A7.6 Continued 
Treatment Group: Timing of Timing of Nature and time after sur-
Reference Protedure(num- combination preincision drug! preincision post incision Systemic gery of preventive or pre-
(year) ber of patients) (Fig. 7.1) postincision drug Routes and doses intervention intervention opioid' emptive analgesic effect 
232 (1996) Abdominal surgery 3;5 GA plus: Thoracic epidural 85 min before - 60 min before fEN Lv. Preventive effect - yes on 
(n=142) G1: G1: 0.2 ml/kg 1% skin incision end of surgery 2 j.!g/kg days 1-2 post operation 
MEP + MOR + MET + DIC/l2l MEP and 75 j.!g/kg followed (221 min after E·PCA: G1 = G2 < G3; 
G2: 01 MOR followed by by epidural start of surgery) days 3-4 postoperation 
MEP + MOR + MET + DIG 0.1 ml/kg 1% MEP q bolus doses E-PCA: Gl < G2 < G3 
G3: 0/0 60min intraoperatively 
G2: 0.2ml/kg 1% q 60min 
MEP and 75 
MOR 
Lv. 
1,000mg MET 
i.m. 
75mg DIC 
233 (1996) Third molar 1;2 GA plus: p.o. p.o. NA ALf Lv. Preventive effect - no 
extraction Gl: PLA + TEN + LID + EPI! Gl: PLA medications 1Oll9/kg 
(n= 40) NA G2: 100mg DIC 60-90 min 
G2: DIG + TEN + LID + EPI! G3: 10mg MTH before surgery 
NA i.v. Lv. TEN soon 
G3: MTH + TEN + LID + EPI/ 20mgTEN after induction, 
NA infiltration before surgery 
8-10 ml 2% LID + 1: infiltration 
100,000 EPI after induction, 
Smin before 
surgery 
234 (1998) Posterolateral 2;3 GA plus: Lv. <: 20 min before At end of No Preemptive effect 
thoracotomy Gl: MOR + DIG + BUP/PLA 10mgMOR start of surgery surgery.20min yes from 12-48h post 
(n=30j G2: PLA/MOR + OIG + BUP Lm. before end of operation 
75mg ole anesthesia Pain on movement: G1 < G2 
intercostal blocks 
40 ml 0.5% BUP 
a. Administered to all patients as a premedication or during surgery. 
ALF. alfentanil; BUP, bupivacaine; Die. diclofenac; E-PCA, epidural patient-controlled analgesia; FEN. fentanyl; GA, general anesthesia; Lm .. intramuscular; IND. indomethacin; ICNB. intercostal nerve block; i.v .. 
intravenous: LID. lidocaine (lignocaine); MEP. mepivacaine; MET. metamizole; MTH. methadone; MID. midazolam; MOR, morphine; NA, not applicable; NS, not stated: p.o .. per os; PER. perphenazine: PlA. pla-
cebo; p.r .. per rectum; SAL, saline; TEN, tenoxicam; 0. nothing administered. 
